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The purpose of this thesis was to examine and quantify the effects of the short-
chain fatty acid acetate, a by-product of the microbial fermentation of dietary fibre, 
on the metabolism of cancer cells, and to test whether acetate can sensitize cells 
to apoptosis induced by anti-cancer drugs, by a process known as priming.  
Methods 
To examine the effects of acetate, several markers of metabolism were assayed in 
3 cell lines HCT116 (Human colon cancer), MCF7 (Human breast cancer) and the 
control cell line MCF10 (non-cancerous human breast) following 24-hour acetate 
treatment in doses ranging from 1-25 mM. Reactive oxygen species and Ca2+ 
were measured with fluorescent spectroscopy. Mitochondrial function was 
measured using the SeaHorse XFE Analyser and 2-photon-NADH FLIM. 
Mitochondrial morphology was assessed with confocal microscopy.  
To determine whether acetate could prime cells for death, changes in proliferation 
were measured with the MTT cell viability assay and levels of apoptosis induction 
were measured with Annexin-V FITC flow cytometry.  
Results 
Acetate induced a state of oxidative stress in the HCT116 and MCF7 cancer cell 
lines, indicated by an average 17.5% significant decrease in mitochondrial basal 
respiration, increased ROS production (significant 24% average increase across 
the two cancer cell lines), and increased Ca2+ levels (significant 22% average). 
Whilst ROS and Ca2+ were elevated in the non-cancerous cell line, there was no 
significant change in mitochondrial basal respiration, suggesting that acetate 
treatment did not cause oxidative stress in healthy cells.  
When cancer cells were primed with 10 mM acetate 24 hours prior to treatment 
with cisplatin, there was an average 1.85-fold increase in apoptosis compared to 
treatment with the drug by itself. This effect was not observed in the non-




Priming has been shown to have the potential to improve the efficacy of pre-
existing chemotherapeutic agents. With cancer incidence increasing worldwide, 
there is a need to improve current treatments without exacerbating side effects 
and impairing patient quality of life. In this thesis, I show that acetate improves the 
effectiveness of cisplatin in inducing apoptosis, by selectively inducing oxidative 
stress in a cancer cell line model. My work highlights a new mechanism for the 
action of acetate and adds further evidence that priming can be used as a safe, 
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1.0 Introduction       
1.1 Cancer 
 
Cancer is a group of widespread and potentially fatal diseases 
characterised by the unregulated proliferation of abnormal cells which, if 
malignant, have the potential to spread to and proliferate in other parts of the 
body. The invasive cells can outgrow the surrounding healthy cells and tissue, 
leading to organ failure and eventually death (World Health Organization, 2017). 
There are over one hundred different types of cancer, which together accounted 
for 8.8 million deaths globally in 2015, making it one of the leading causes of death 
worldwide (World Health Organization, 2018). The risk of cancer increases with 
age (Cancer Research UK, 2018), and the rate of cancer incidence worldwide is 
increasing, particularly in developing countries, as a result of aging populations 
and the rising prevalence of cancer-associated lifestyle choices, such as smoking, 
alcohol consumption, diet, physical inactivity (Jemal et al., 2011), and obesity 
(Flegal et al., 2013). Although a predisposition to cancer can be inherited, it is 
estimated that lifestyle and environmental factors account for 90-95% of all cancer 
cases (Anand et al., 2008). The total economic impact of cancer, as a 
consequence of premature death and disability, was estimated to be $1.6 trillion in 
2010,  equating to over 1.5% of the World’s Global Domestic Product (GDP) 
(Livestrong and American Cancer Society, 2010).  
The term cancer refers to the disease state wherein the mechanisms that 
regulate cell growth, division, and death fail, resulting in the accumulation of 
abnormal cells known as a tumour or neoplasm (Bertram, 2000). Cancerous 
tumours are malignant, meaning they have the potential to spread from their site of 
origin to other parts of the body; a process called metastasis (National Cancer 
Institute, 2015). Tumours that do not spread are considered benign and often can 
be removed by surgery. Although there is a smaller chance of metastasis, benign 
tumours can still pose risk to the patient by compressing surrounding tissue, 
causing nerve damage (Giglio and Gilbert, 2010) and ischemia (Noje et al., 2009). 
17 
 
In addition, benign tumours have the potential to become malignant if left 
untreated (Clark, 1991).  
Historically, the development and growth of a tumour was considered to be 
driven by mutations or changes in the level of expression of genes that regulate 
the division or removal of cells, broadly categorised into oncogenes or tumour 
suppressor genes (Croce, 2008) (Figure 1). Oncogenes encode proteins that 
control the proliferation or removal of cells. In cancer, these are often mutated or 
expressed at high levels. In contrast, tumour suppressor genes govern a wider 
range of cellular processes that protect against cancer, such as cell cycle control, 
protein turnover, and DNA (deoxyribonucleic acid) damage repair (Sherr, 2004). In 
cancer, these genes are under-expressed or express mutated, disabled proteins. 
Currently, the Catalogue of Somatic Mutations in Cancer (COSMIC) database lists 
719 genes for which mutations in are causally implicated in cancer (Futreal et al., 
2004). In addition to oncogenes and tumour suppressor genes, microRNA (micro 
ribonucleic acid, or miRNA) genes, which code for small, non-coding RNAs, are 
also implicated in tumorigenesis and resistance to treatment (Fadejeva et al., 
2017). miRNAs have roles in the regulation of gene expression and as such, 
dysregulated expression of miRNAs can in turn affect the expression of 
oncogenes or tumour suppressor genes (Peng and Croce, 2016). A mutation in a 
single oncogene or tumour suppressor is not usually sufficient to cause cancer 
alone; rather, mutations accumulate as a result of other mutations. For example, a 
mutation in a gene that repairs damaged or mutated DNA can lead to the 
propagation of more faulty genes, and in a chain reaction-like system, a cell can 
accumulate an increasing number of mutations, and so become more resistant to 
the machinery regulating normal cell proliferation (Merlo et al., 2006). With 
sufficient growth and mutations, tumour cells can penetrate into the circulatory 
system and spread to other tissues – a process known as metastasis. Once a 
tumour has metastasised, the patient’s prognosis becomes substantially worse 









More recently, evidence indicates that cancer may rather be primarily a 
disease of metabolic disorder, and that genomic instability is a consequence of an 
initial metabolic disturbance rather than the cause of it (Seyfried et al., 2014). This 
remains a provocative viewpoint in cancer research, as the somatic mutation 
theory (SMT) of cancer origin, as it became known, was near universally accepted 
and drove cancer research for decades (Soto and Sonnenschein, 2004). 
Nevertheless, inconsistences in SMT led scientists to question the theory, 
including early experiments which showed that combining the cytoplasm of a non-
cancerous cell with the nucleus from a tumour cell led to reduced tumourgenicity 
(Israel and Schaeffer, 1987), and more recent experiments that showed that 
transfer of normal mitochondria into tumour cells inhibited proliferation and 
increased drug sensitivity  (Elliott et al., 2012). Whilst there remain arguments 
against tumorigenesis being driven solely by metabolism, such as in immune cells 
Figure 1 | Oncogenes and Tumour Suppressors: Mechanisms of Carcinogenesis. On the left, 
activation of oncogenes results in rapid cellular proliferation. On the right, deactivation of 
tumour suppressor genes removes the regulation of proliferation. 
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that adopt different metabolic phenotypes in response to antigens yet rarely form 
tumours (Altman and Dang, 2012), the increasing recognition of cancer as a 
metabolic disease provides exciting implications for the future of cancer treatments 
(Coller, 2014). 
 
1.2 | Cancer Cell Metabolism  
 
1.2.1 | The Hallmarks of Cancer 
  
The hundreds of oncogenes or tumour suppressor genes, not counting 
genes for which altered levels of expression or epigenetic changes are linked to 
cancer (Futreal et al., 2004), creates a large number of possible genotypes which 
generates enormous heterogeneity and complexity, even within similar types of 
cancer, which has significant clinical implications (Marusyk and Polyak, 2011). 
Despite this, cancers have been generally observed to share several key 
characteristics, which became known as the “Hallmarks of Cancer” (Hanahan and 
Weinberg, 2000) (Figure 2).  
In 2011, these original hallmarks were revised to include genomic 
instability, inflammation, evasion of the immune system, and the reprogramming of 
energy metabolism, necessary to fuel the “limitless replicative potential” of cancer 







Figure 2 | The Hallmarks of Cancer. In spite of the complex genetic variety of cancer, Hanahan 
and Weinberg proposed 9 characteristics that are observed in all cancer cells. Later, Pavlova and 
Thompson proposed a further 6 metabolic features that are generally conserved in cancer cells   
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1.2.2 The Metabolic Hallmarks of Cancer 
 
The accelerated rate of proliferation in cancer creates new metabolic demands 
of the cell: to ensure survival in stressful nutrient depleted conditions, and to 
support the enhanced energetic and biosynthetic needs of rapid growth (De 
Berardinis and Chandel, 2016). To meet these demands, cancer cell metabolism 
is often altered relative to healthy cells. Some of these alterations are sufficiently 
well-conserved across different types of cancer that the reprogramming of cellular 
metabolism is considered a hallmark of cancer.  
One of the first and most well-known changes that was identified was the shift 
in energy production from oxidative phosphorylation (OXPHOS) to the anaerobic 
process of glycolysis despite the presence of adequate oxygen, known as the 
Warburg Effect (Warburg, 1956).  A decrease in oxygen dependence can confer a 
proliferative advantage to cancerous cells; allowing cells to migrate and thrive 
further from the oxygen-rich environment around blood vessels (Hsu and Sabatini, 
2008). Substrates that would normally be consumed in OXPHOS and the 
tricarboxylic acid (TCA) cycle are diverted into catabolic processes that produce 
fatty acids, essential for rapid cellular proliferation.   
Metabolic changes in cancer cells are now a substantial field of research itself. 
Progressing from Hanahan & Weinberg’s Hallmarks paper, Pavlova and 
Thompson went on to describe six additional hallmarks of cancer metabolism 
(Figure 2) (Pavlova and Thompson, 2016): 
1.) Deregulated uptake of glucose and amino acids 
2.) Use of opportunistic modes of nutrient acquisition 
3.) Use of glycolysis/TCA cycle intermediates for biosynthesis 
4.) Increased demand for nitrogen 
5.) Alterations in metabolite-driven gene regulation 
6.) Metabolic interactions with the microenvironment 
Common deregulated mechanisms include the excessive activation of 
phosphoinositide 3-kinase (PI3K), which through the protein kinase (Akt) and 
mechanistic target of rapamycin (mTOR) signalling pathways can enhance 
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glucose uptake into the cell via the glucose transporter 1 (GLUT1), and inhibit the 
entry of metabolites into the TCA Cycle, thus conferring increased cellular 
dependence on glycolysis (Courtnay et al., 2015), or increased gain of function of 
MYC, a gene encoding a transcription factor, c-MYC, which amplifies the 
expression of genes that promote cellular growth and proliferation (Stine et al., 
2015). Tumour protein p53 (TP53), which encodes p53 is another notable 
example; primarily associated with roles in DNA repair, cell cycle arrest and 
apoptosis, loss of p53 has also been associated with increased glycolysis 
(Kruiswijk et al., 2015). 
 
1.3 | The Mitochondria & Their Role in Cancer 
 
Otto Warburg attributed his observation that cancer cells seemed to ferment 
glucose despite the presence of oxygen to defects in mitochondrial respiration, 
since OXPHOS occurs in the mitochondria. Nowadays, it is generally accepted 
that far from being defective, mitochondria in fact play key multifunctional roles in 
tumorigenesis and cancer cell progression (Zong et al., 2016). This is further 
demonstrated by the observation that removing mitochondrial DNA from a cell 
delays tumour growth (Tan et al., 2015). Furthermore, cancer cells that rely more 
on glycolysis still retain fully functional mitochondria (Zu and Guppy, 2004). 
Mitochondria are double-membrane bound organelles with integral roles in 
cell metabolism – through the TCA cycle and OXPHOS they supply the majority of 
a cell’s energy, and are also vital in a number of essential cellular functions, 
including various signalling, biosynthetic, and cell death pathways. In cancer, 
mutations in mitochondrial genes perturb the bioenergetics and biosynthetic states 
to support the altered requirements of the cells (Brandon et al., 2006). As such, 
the mitochondria are essential for cancer cell growth, proliferation and survival 
(Wallace, 2015). The following sections describe the key functions of 
mitochondria, and how impaired or modified function can contribute not only to the 




1.3.1 | Mitochondrial Morphology & Dynamics 
 
The mitochondrial membranes consist of an outer mitochondrial membrane 
(OMM) facing the cytosol, and the inner mitochondria membrane (IMM) encasing 
the mitochondria’s inner space; the matrix. The IMM is folded into protrusions 
called cristae, increasing the surface area for the biochemical processes, such as 
OXPHOS, that occur within or across it.  
Classically depicted as discrete, tubular structures, typically between 0.75 
and 3 µM in diameter, mitochondria are in fact dynamic structures that can fuse 
into long, elongated networks, split into smaller, singular structures and move 
along microtubular networks, depending on the cell’s energetic requirements 
(Senft and Ronai, 2016). Mitochondrial fusion and fission are tightly controlled 
processes, regulated by a number of proteins including the cytosolic dynamin 
related protein (Drp1) (Smirnova et al., 2001), human mitochondrial fission protein 
1 (hFis1) (Yoon et al., 2003) and the mitochondrial dynamin-like GTPase (Opa1) 
(Meeusen et al., 2006). Fusion of mitochondria into elongated networks is 
associated with increased ATP production (Youle and van der Bliek, 2012), and 
has also been seen to act as a mitochondrial repair mechanism, with healthy 
mitochondria fusing to damaged ones and removing the damaged parts (Youle 
and van der Bliek, 2012). Fission of mitochondria into a more fragmented state on 
the other hand has been identified as an early pre-requisite step in programmed 
cell death (PCD) (Suen et al., 2008) and has also been identified as a quality 
control mechanism – allowing unrepairable mitochondria to be “teased apart” from 
the rest of the network, and then targeted for lysosomal degradation in a process 
known as mitophagy (See section 1.3.2) (Higuchi-Sanabria et al., 2018). The 
proteins that regulate fusion or fission events have themselves been shown to 
have key roles in programmed cell death; the down regulation of Drp1 and hFis1; 
mitochondrial fission proteins, induce a resistance to apoptosis, whilst down 
regulation of Opa1, which regulates fusion, enhances sensitivity to apoptosis (Lee 





1.3.2 | Autophagy, Mitophagy, & Mitochondrial Biogenesis 
  
Autophagy describes the regulated destruction of cellular components. This 
process is utilized by cells to remove unnecessary or dysfunctional organelles, or 
to promote survival in conditions of starvation to maintain cellular energy levels via 
a process akin to recycling (Mizushima and Komatsu, 2011). Since the removal of 
malfunctioning organelles is essential for healthy cellular function, autophagy has 
a key role in preventing a range of diseases. Impaired or excessive autophagy is 
linked neurodegenerative disease, cardiac disease, infection, and cancer (Levine 
and Klionsky, 2004). 
 Being at the centre of cellular metabolism and energy production, the 
selective degradation of mitochondria, known as mitophagy, is of specific interest 
to researchers, particularly with respect to its role in disease. The accumulation of 
damaged mitochondria as a consequence of impaired mitophagy can lead to 
Parkinson’s Disease (Narendra et al., 2009) and is implicated in ageing (Shi et al., 
2017), with the pathogenesis of both being tied to increased oxidative stress, 
decreased Ca2+ buffering, and loss of ATP.  
 The biogenesis of mitochondria is essential to maintaining healthy cellular 
homeostasis. The removal of superfluous mitochondria and production of 
additional mitochondria is dictated largely by the energetic demands of the cell. 
The synthesis of mitochondria is therefore considered a stress response to 
counteract decreases in ATP production (Lee and Wei, 2005).  Biogenesis, like 
mitophagy, is a highly regulated and complex process (Poyton and McEwen, 
1996). The mitochondria, possessing its own DNA, must replicate, transcribe and 
translate it’s genome in coordination with mitochondrial genes within the nucleus 
and direct these proteins to the appropriate space to form the mitochondria.  
 Mitophagy and mitochondrial biogenesis are regulated by communication 
between the mitochondria and nucleus, which contains genes for both 
mitochondrial genesis and autophagy regulation. The communication is referred to 
as mitochondrial retrograde (mitochondria to nucleus) or anterograde (nucleus to 
mitochondria) signalling. In both pathways, signals between  mitochondria  and 
nucleus effect changes in nuclear gene transcription in order to reconfigure cellular 
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metabolism based on cellular demands or mitochondrial health (Liu and Butow, 
2006; Ng et al., 2014).  
 
1.3.3 | Mitochondrial DNA 
 
The mitochondria contains its own DNA; a circular genome of 16,569 base 
pairs. In addition to ribosomal RNAs and transfer RNAs (tRNAs), 13 polypeptides 
are encoded, which make up some of the complexes of the electron transport 
chain (ETC) (described in section 1.5.1) (Anderson et al., 1981). Aside from its 
circular structure, mitochondrial DNA (mtDNA) possesses several features that 
differentiate it from nuclear DNA. It contains no introns, but rather a single non-
coding region called the displacement loop (D-Loop) (Lee and John, 2015). The 
function of the D-loop has yet to be fully resolved, but researchers have identified 
a protein, ATAD3p, as having a high affinity for the D-loop, which when silenced 
resulted in the disruption of the structure of mitochondrial nucleoids, suggesting 
the D-loop plays a role in maintaining mtDNA organisation and structure (He et al., 
2007).  
Despite its small size compared to the nuclear genome, the essential 
functions regulated by the mitochondria mean that mutations that occur in mtDNA 
can manifest in a range of diseases in many different tissues with a wide variety of 
clinical features, including diabetes, hearing loss, infantile encephalopathy (Taylor 
and Turnbull, 2005) and tumour formation (Gasparre et al., 2008). Indeed, mtDNA 
mutations have been detected in a large percentage of cancers, yet whilst 
mutations that occur in coding regions have the potential to disrupt the cell’s 
energy production and redox state, most have been found to occur in the control 
region of the genome, which would suggest that it is unlikely mtDNA mutations 
drive tumour growth (Kirches, 2017). The role of mtDNA in tumour development is 
further complicated as each cell contains multiple mitochondria each with their 
own copies of mtDNA, meaning wild type and mutant mtDNA can co-exist within a 
cell in a state called heteroplasmy. Thus, the biological impact of mtDNA 
mutations depends on the proportion of mitochondria within a cell containing 
mutated mtDNA compared to mitochondria with no mutations (Chatterjee et al., 
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2006). The overall copy number of mitochondria has been observed to be 
decreased in cancer relative to normal cells, correlated in some types with 
reduced expression of respiratory genes. On the other hand, tumours with high 
mtDNA content, which may confer increased mitochondrial dependence, may 
present a vulnerability to mitochondria targeted therapies (Reznik et al., 2016).  
 
1.3.4 | Mitochondrial Metabolism 
 
The mitochondria are primarily associated with the production of the cell’s 
energy-rich substrate, adenosine triphosphate (ATP), through the aerobic pathway 
of OXPHOS. Embedded on the inner membrane of the mitochondria are a series 
of 5 protein complexes which make up the ETC, which catalyse a series of redox 
reactions, transferring electrons from high-energy donors to acceptors (See Table 
1). The energy released in these reactions is used to generate a transmembrane 
proton gradient across the inner mitochondrial membrane, which drives the 
production of ATP from the final complex in the chain, ATP synthase. The final 
electron acceptor in the process is oxygen, making the process aerobic. OXPHOS 

















COMPLEX NAME REACTION 
I NADH Dehydrogenase 
Transfer of  electrons from 
NADH to ubiqunone (UQ) to 
form ubiquinol (UQH2) 
II Succinate Dehydrogenase 
Transfer for electrons from 
succinate to ubiqunone 
(UQ) to form ubiquinol 
(UQH2) 
III Cytochrome bc1 
Electrons from the quinone 
pool are transferred to 
cytochrome c 
IV Cytochrome c oxidase 
Electrons from reduced 
cytochrome c are 
transferred to molecular 
oxygen to produce water 
V ATP Synthase Produces ATP 
Table 1 | Complexes of the Electron Transport Chain. Imbedded in the inner mitochondrial 
membrane, Complexes I through IV pump protons derived from metabolic intermediates into the 





OXPHOS occurs on and across the inner membrane of the mitochondria. In 
the matrix another energy releasing pathway occurs: the TCA Cycle, also known 
as the citric acid cycle or Kreb’s cycle. The TCA cycle starts with acetate, in the 
form of acetyl coenzyme A (Acetyl CoA), produced from sugar, fat, and protein 
catabolism, and ends with the production of carbon dioxide and the electron 
carriers flavin adenine dinucleotide (FADH2) and nicotinamide adenine 
dinucleotide (NADH), which shuttle the high-energy electrons, derived from the 
catabolism of the sugars, fats, and amino acids, to the ETC (Nelson and Cox, 





Figure 3 | The Electron Transport Chain. Through Complexes I-IV, metabolic intermediates 
are reduced to produce high energy electrons (blue arrows), which push protons (red arrows) 
across the inner mitochondrial membrane, generating an electrochemical gradient between 
the intermembrane Space and the Matrix. This gradient drives the production of ATP from 
Complex V, also known as ATP Synthase. 
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Figure 4 | The Tricarboxylic Acid (TCA) Cycle. The TCA cycle is a series of reactions that 
produces CO2, ATP, NADH and FADH, starting with the oxidation of acetyl CoA. As well as 
producing energy itself in the form of ATP, NADH and FADH are used in the electron transport 




1.3.5 | The Mitochondria and the Production of Reactive Oxygen Species 
 
Reactive oxygen species (ROS) describes a number of highly reactive 
chemicals, all of which originate from molecular oxygen (O2) (Table 2). ROS are a 
natural by-product of mitochondrial respiration, in particular from Complexes I and 
III in the ETC (Holmström and Finkel, 2014). Members of the ROS family, such as 
hydroxyl radicals and superoxide anions, are extremely reactive and can cause 
DNA and RNA damage, excess oxidation of amino acids, and deactivation of 
enzymes if levels are allowed to accumulate – a state known as oxidative stress 
(Sosa et al., 2013).  
SPECIES SOURCE ACTION 
















To prevent oxidative stress, ROS levels are regulated by a cell’s antioxidant 
defences, which includes enzymes such as catalase and superoxide dismutase 
(SOD), which catalyse the decomposition of hydrogen peroxide into water and 
oxygen and the conversion of the superoxide radical into oxygen (Birben et al., 
2012). Owing to their reactive and destructive properties (see Table 2), for a long 
time ROS had been perceived as largely toxic and harmful, associated with a 
variety of diseases including asthma, hypertension, and retinopathy (Auten and 
Davis, 2009). The increased incidence of cancer at older age has been attributed 
to elevated ROS, for example through a decline in ROS clearing enzyme-activity 
Table 2 | The Reactive Oxygen Species produced from mitochondrial respiration, with the mode 
of action of each. Hydrogen peroxide and the hydroxyl radical are not directly produced by the 
mitochondria, but are rather produced as side effects of the removal of the superoxide anion. 
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at older age (Van Remmen et al., 2003). Oxidative stress was also considered to 
be a major cause of aging: numerous studies have demonstrated that ROS 
accumulates in an organism as it ages, and that reducing oxidative damage 
extends the lifespan of model organisms. This became known as the free radical 
theory of aging (Beckman and Ames, 1998). This theory, and the overall 
consensus that ROS are largely deleterious to organisms, is being increasingly 
challenged by more recent research which identifies ROS as vital molecules for a 
number of essential cell signalling pathways (Gladyshev, 2014). For example, 
deletion of sod-2, encoding the antioxidant protein SOD, extended the lifespan of 
the model organism Caenorhabditis elegans (Van Raamsdonk and Hekimi, 2009).  
Examples of ROS-dependent signalling pathways include the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) pathway, which is 
implicated in a number of cellular processes including cell adhesion and 
differentiation, and the mitogen activated protein kinase (MAPK) pathway, crucial 
in cell growth and cell death (Jixiang Zhang et al., 2016). Furthermore, ROS 
production and removal affects the balance of oxidation and reduction reactions in 
a cell, known as the cell’s redox state. Interestingly, the redox state of the cell 
fluctuates during the cell cycle, which led researchers to propose the production of 
ROS, controlling the redox state, can regulate cellular proliferation (Sarsour et al., 
2009). Direct ROS/redox regulation of a number of cell-cycle proteins, including 
p21 and cyclin D1, has been observed in vitro (Fitzgerald et al., 2015; Lim et al., 
2008).  
 
1.3.5.1 | ROS and Cancer 
 
In cancer cells the levels of ROS can be increased, enhancing the 
metabolic rate of the pathways described above, particularly those involved in 
cellular proliferation (Sullivan and Chandel, 2014). At the same time, cancer cells 
also increase their anti-oxidant capacity to protect against oxidative stress and cell 
death (Reczek and Chandel, 2018) (See Figure 5). For example, the transient 
receptor potential cation channel 1 (TRPA1), over-expressed in cancer, is 
activated by ROS, leading to the influx of Ca2+ which serves to upregulate Ca2+ 
dependent anti-apoptotic survival pathways (Takahashi et al., 2018).  
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Changes in the redox state of cancer cells are inextricably linked to 
hallmark changes in cellular metabolism. Intermediates from glycolysis, elevated in 
cancer cells, are funnelled into pathways such as the pentose phosphate pathway 
(PPP), which produces ribose-5 phosphate, a precursor to nucleotide synthesis as 
well as nicotinamide adenine dinucleotide phosphate (NADPH), a molecule 
involved in ROS removal (Described in more detail in Section 1.3.8) (Panieri and 












Figure 5 | ROS in Cancer: A Double-Edged Sword. Elevated ROS in cancerous cells, produced 
primarily by the electron transport chain within the mitochondria, can promote tumorigenesis. 
If ROS levels continue to rise, it can cause oxidative stress which can lead to cell death. To 
prevent this, cancer cells can increase antioxidant defences. 
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1.3.6 | Mitochondria and Calcium Signalling 
  
Calcium ions (Ca2+) are of vital importance in the physiology of cells. 
Ubiquitous in cellular signalling pathways, Ca2+ can interact directly in processes 
such as apoptosis, protein conformation and localisation, or indirectly as a second 
messenger in almost all receptor-based signalling pathways (Clapham, 2007). The 
calcium based signalling mechanism is based on changes in the amplitude, 
frequency, duration, and localization of cytosolic calcium ([Ca2+]c). Such 
spatiotemporal changes arise from the entry of Ca2+ into the cell from the 
extracellular matrix, or the release of Ca2+ from various intracellular stores, notably 
the mitochondria, as well as the endoplasmic reticulum and the Golgi apparatus 
(Contreras et al., 2010). Thus, by acting as Ca2+ buffers for the cytosol, these 
organelles play key roles in cellular signalling.  
 Ca2+ freely diffuses through the outer mitochondrial membrane, primarily 
through the voltage dependent anion channel (VDAC), a large, weakly selectively 
anion channel, abundant on the OMM. VDAC can assume open or closed 
conformations, a feature which plays a key role in the regulation of apoptosis 
(Rizzuto et al., 2010). Transport across the inner membrane into the matrix is 
driven by the electrochemical gradient generated across the membrane by the 
ETC through ion channels – notably the mitochondrial calcium uniporter (MCU) 
(Kirichok et al., 2004). Efflux out of the mitochondria is mainly attributed to the 
Na+-Ca2+-Li+ exchanger (NCLX). As will be described in sections 1.3.6.1 and 
1.3.6.2, mitochondrial Ca2+ ([Ca2+]m) flux is key in vital cell processes such as 
energy metabolism and cell death. Therefore, disruptions to the mitochondrial Ca2+ 
transport machinery can manifest in a variety of pathologies, such as 
tumorigenesis and oxidative stress (Marchi and Pinton, 2014). The entire picture of 
Ca2+ transport has yet to be fully realised, highlighted by studies in MCU deficient 
mice, which although exhibited an impaired ability to perform “strenuous work”, 
unexpectedly showed no alteration in basal metabolism rates (Pan et al., 2013), 
suggesting the activity of other Ca2+ influx transporters can be enhanced to 
maintain a level of Ca2+ homeostasis (Marchi and Pinton, 2014).   
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1.3.6.1 | Mitochondrial Ca2+ and Metabolism 
  
Aside from maintaining [Ca2+]c  homeostasis, mitochondrial Ca2+  affects the 
rates of mitochondrial respiration through the allosteric activation of a number of 
mitochondrial enzymes, including pyruvate dehydrogenase, the activation of which 
increases NADH supply and thus ATP production, and ATP synthase (Complex 
V), increasing the output of ATP (Griffiths and Rutter, 2009). This general 
upregulation of the mitochondrial metabolic machinery by Ca2+ provides the cell a 
signalling pathway to modify ATP production to meet energetic demand (Bianchi et 
al., 2004). 
 
1.3.6.2 | Mitochondrial Ca2+ and Cell Death 
  
It is now well established that mitochondria play key role in the regulation 
and initiation of apoptosis and other forms of cell death (Martinou and Youle, 
2011), the minutiae of which are discussed in Section 1.6. An initial step in 
mitochondrial-regulated cell death is the formation of the permeability transition 
pore (PTP) on the outer membrane of the mitochondria. This perforation of the 
membrane releases pro-apoptotic factors such as cytochrome c or apoptosis 
inducing factor (AIF) into the cytosol, which then go on to activate the apoptotic 
machinery (Orrenius et al., 2015). The opening of these pores is enhanced by the 
sustained mitochondrial accumulation of Ca2+ (also known as Ca2+ overload) 
(Lemasters et al., 2009). Further to this, the subsequent depolarization of 
mitochondria caused by Ca2+ overload in a particular sub-cellular region initiates a 
wave of further mitochondrial Ca2+ uptake and depolarization, propagating an 





1.3.7 | The Interplay Between Mitochondrial Ca2+, ROS, and Morphology 
  
There exists a complex interaction between the signalling molecule, Ca2+ 
and the by-products of mitochondrial respiration, ROS (Figure 6). For example, 
mitochondrial Ca2+ overload can also lead to enhanced generation of ROS 
(Kowaltowski et al., 1998). The mechanisms of this production are not yet fully 
understood. It has been suggested that Ca2+ causes a conformational change in 
Complex I, and can indirectly inhibit Complex III through the production of nitric 
oxide (NO), both mechanisms inducing ROS production (Feissner et al., 2009) 
Additionally, the increase in the mitochondrial respiratory rate driven by [Ca2+]m 
leads to a subsequent increase in ROS production. Increases in mitochondrial 
Ca2+ concentration ([Ca2+]m) or ROS can enhance the concentration of the other, 
creating a positive feedback loop that, if not broken by the mitochondria’s anti-
oxidant defences or by mitochondrial Ca2+ efflux channels, can lead to a state of 
oxidative stress or cell death by apoptosis (Feissner et al., 2009).  
 Ca2+ is also suspected to have a role in regulating mitochondrial dynamics; 
it has been shown that increases in [Ca2+]c inhibit mitochondrial movement and 
can cause changes in morphology from an elongated to a more rounded shape 
(Szabadkai et al., 2006). This relationship is thought to be mediated by 
interactions between Ca2+ and the proteins that regulate mitochondrial morphology 
such as Drp1 and hFis1 for fission, and Mfb1 and Opa1 for fusion (Jeyaraju et al., 
2009). The extent of the mitochondrial network and the distribution of mitochondria 
in general has a profound effect on the mitochondrial-based Ca2+ signalling. For 
example; fragmentation of the mitochondrial network has been shown to inhibit the 




Figure 6 | Calcium Interactions with the Media. Calcium is taken up by the mitochondria from 
areas of high [Ca2+]c, such as those in proximity to the endoplasmic reticulum. Ca2+ moves 
passively across the outer mitochondrial membrane via VDAC. From the intermembrane 
space, Ca2+ is moved into the mitochondrial matrix through the MCU complex, and is removed 
via NCLX. Increases in [Ca2+]m stimulate increased OXPHOS rates and ROS production. 
Sustained high [Ca2+]m can result in mitochondrial fission and the opening of mPTP (including 
VDAC), both of which can lead to apoptosis. Increases in [Ca2+]m can trigger the enhanced 
uptake of Ca2+ in neighbouring mitochondria, allowing the propagation of a Ca2+ signalling 




1.3.8 | NADH Metabolism 
  
The pyridine nucleotides, nicotinamide adenine dinucleotide (NAD) and 
nicotinamide adenine dinucleotide phosphate (NADP) are two molecules which, as 
electron carriers, play important roles in cellular redox chemistry. NAD exists in 
oxidised (NAD+) and reduced (NADH) forms.  The redox chemistry of NAD links 
the major energy producing pathways in the cell: the conversion of pyruvate into 
acetyl CoA in glycolysis yields NADH, which can transfer electrons to NADH 
dehydrogenase, also known as Complex I, in the mitochondrial ETC. The resulting 
NAD+ can then be reduced in the TCA cycle, allowing the cycle of NAD+ to NADH 
to perpetuate (Blacker and Duchen, 2016). 
 Whilst NAD/NADH primarily acts as an electron donor in these energy-
producing or catabolic pathways, NADP/NADPH has a somewhat counter-role, 
regulating antioxidant defences that protect the cell from oxidative stress, caused 
by the production of ROS as a side-effect of OXPHOS. Two such antioxidant 
systems, glutathione and thioredoxin, act as a first line of defence against the 
accumulation of hydrogen peroxide (H2O2), which itself is produced by the 
neutralisation of superoxide, another reactive species. In these systems, enzymes 
catalyse the reduction of H2O2 into water through the oxidation of glutathione 
(GSH) and thioredoxin (TRX) respectively. Glutathione reductase and thioredoxin 
reductase then restore GSH and TRX back to their reduced forms, the electrons 
for which are provided by NADPH (Blacker and Duchen, 2016). In a stark contrast 
to this anti-oxidant activity, NADPH also has a role in the “intentional” production of  
the ROS superoxide through NADPH oxidase enzymes (known as NOXs), 






 1.4 | Targeting Cancer Metabolism  
 
The alterations in metabolism, as described in the previous sections, whilst 
proving advantageous for cancer cell proliferation, can potentially present a target 
for treatments. For example, targeting glycolysis through the inhibition of the 
glucose transporter 2 (GLUT2) (Wu et al., 2009) or the glycolytic pathway enzyme 
hexokinase (Maschek et al., 2004) were shown to induce apoptosis in cancer cells 
or to enhance the efficacy of anti-cancer drugs. Reversal of the Warburg Effect 
has also shown potential as a novel treatment: in glioblastoma, increased oxygen 
consumption conferred to a decrease in proliferation (Poteet et al., 2013), and in 
melanoma cell lines, a “reversal of the metabolic switch” by inhibiting glycolysis led 
to cell cycle arrest and enhanced sensitivity to apoptosis (Bettum et al., 2015). 
Metformin, a complex I inhibitor commonly used to treat the metabolic disorder 
type 2 diabetes has been found to have additional anticancer properties in diabetic 
patients by inhibiting the mTOR signalling pathway (Zi et al., 2018). Furthermore, 
enhancing mitochondrial ROS production has been used to improve sensitivity to 
anticancer drugs (Yun et al., 2015). Manipulating the cell’s ability to remove 
dysfunctional mitochondria by targeting autophagy and mitophagy is also being 
investigated as a novel target (Mathew et al., 2007).  
 
1.5 | Cancer Chemotherapy 
 
Historically, the treatment of cancer uses a single or a combination of 3 
treatment approaches: surgery, radiotherapy, and chemotherapy (Cancer 
Research UK, 2017). Other approaches, such as hormone therapy (Vorobiof, 
2016) or immunotherapy (Vorobiof, 2016) are being developed and improved 
continuously. Whilst surgery and radiotherapy are effective at removing solid, 
localised tumours from the body, chemotherapy is often used in conjunction with 
these approaches to improve their effectiveness, or as the primary course of 
treatment for non-solid cancers such as leukaemia, or to treat cancers that have 
spread from their site of origin (NHS, 2017).  
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Early chemotherapeutic drugs originated from the research of chemical 
weapons, such as mustard gas, to treat cancers (Goodman et al. 1946). Although 
modern chemotherapy has since moved towards a more regulated, targeted 
approach, in many cases the primary mode of action for a wide range of anti-
cancer drugs is targeting the rapid proliferation of cancer cells; one of the 6 
hallmarks of cancer. As a consequence, healthy cells with a naturally high rate of 
proliferation, such as those found in hair roots or in the lining of the gut, are also 
affected, meaning that chemotherapy is often accompanied by a number of often 
severe side effects (American Cancer Society, 2016).  
 
1.5.1 | Types of Chemotherapy 
 
The end result of most chemotherapeutic drugs is cell death by apoptosis, 
although the route through which this process is triggered varies enormously 
between the vast number of drugs available. Table 3 summarises the major 
categories of chemotherapy with some examples, highlighting the variation in drug 
mechanism. Section 1.5.2 then discusses the mode of action of cisplatin, selected 






CATERGORY  MECHANISM EXAMPLES 
Alkylating Agents Akylation of DNA, triggering cell death 






Inhibition of unregulated 
phosphorylation  (Gaumann et al., 
2016) Dasatinib, Erlotinib  
Topoisomerase 
Inhibitors 
Inhibition of DNA repair and 
transcription cancers (Xu and Her, 
2015) Camptothecin, doxorubicin  
Antimetabolite  Inhibition of metabolic pathways 5FU, Methotrexate 
Table 3 | Types of Chemotherapy Drugs. Despite the large number of commercially available 
chemotherapy drugs, many share common underlying mechanisms and are often grouped into 
categories. This table, whilst not exhaustive, highlights some common drugs and their 
mechanisms. Different types of chemotherapy drugs are often used in combination, which is 
referred to as combination therapy. 5FU: 5-florouracil 
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1.5.2 | Cisplatin 
 
Diaminedichloridoplatinum (DDP), also known as cisplatin, is one of the 
most widely used and potent anti-cancer drugs available (Siddik, 2003). As an 
alkylating agent, its primary mode of action is through the damage of a cell’s DNA, 
inducing apoptosis (Figure 7). Cisplatin is thought to enter cells through passive 
diffusion, although the membrane-bound copper transporter I (CTR1, involved in 
copper homeostasis) and copper-extruding P-Type ATPases have also been 
implicated as contributing elements (Lin et al., 2002).  
  
Figure 7 | Mechanisms of Cisplatin. Cisplatin enters the cell through passive diffusion or 
facilitated by CTR1. Inside the cell, the complex is activated through aquation. The activated 
complex binds to and distorts the DNA double helix. When the cell fails to repair the resulting 
lesion, apoptosis is initiated.  
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Once inside the cell, cisplatin is hydrolysed to produce mono or di-aqua 
complexes (aquation). Water displaces one or both Cl ions as a consequence of 
the difference in chloride concentrations between the blood stream and cytosol. 
These “activated” complexes can react with the nucleophilic centres on guanosine 
and adenosine – the purine bases of DNA. These reactions can result in the 
formation of a “cross-bridge” between adjacent or inter-strand guanine residues. 
This cross-linking is thought to account for the majority of cisplatin’s cytotoxicity, 
as the resulting distortion of the DNA helix triggers the DNA repair process, which 
upon failure initiates apoptosis (Dilruba and Kalayda, 2016).  
 
1.5.2.1 | Cisplatin Cytotoxicity & ROS  
 
The use of many chemotherapeutic agents, including cisplatin, is limited by 
the damaging side effects they induce. Among these is the enhanced production 
of mitochondrial reactive oxygen species (Marullo et al., 2013). Cisplatin has been 
shown to accumulate in the mitochondria and to bind to mitochondrial DNA 
(mtDNA). Unlike nuclear DNA, mtDNA lacks any excision repair mechanism, 
which results in inhibition of protein synthesis. In turn, this leads to a drop in levels 
of proteins associated with the ETC, and therefore a subsequent deterioration in 
metabolic function and an increase in ROS production (Choi et al., 2015). 
 
1.5.3 | Chemotherapeutic Drug Resistance & Recurrence  
  
Much like bacteria becoming resistant to antibiotics, cancer can develop 
resistance to drugs, which has an impact on the treatment of patients as well as 
the research and development of new anti-cancer agents. In a recent review, 
Housman et al. outline several categories of mechanisms by which cancer can 
exhibit resistance. These include drug efflux, DNA damage repair, cell death 
inhibition, drug target alterations, drug inactivation, and epigenetics, all of which 
can operate independently or in combination (Housman et al., 2014). Drug 
resistance often arises following initial treatment with chemotherapy. This 
development comes from the heterogeneity of a tumour cell population: although a 
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majority of cells are killed following the initial treatment, a small, resistant 
population can survive and remain undetected, and eventually form a new tumour 
which is now resistant to therapy (Cree and Charlton, 2017). Despite a wealth of 
statistics and data regarding cancer incidence and survival, data regarding 
recurrence is surprisingly sparse. In a study of 1000 patients diagnosed with 
breast cancer, Walkington et al. found that 21.4% of patients developed recurrent 
disease within 10 years following initial treatment (Walkington et al., 2012).  The 
risk of recurrence also has a marked effect on a patient’s psychological well-being. 
In a study of 752 patients, Baker et al. found that over half (68.1%) feared that the 
disease would return (Baker et al., 2005).   
 
1.5.4 | Chemotherapy Side Effects 
 
Cancer chemotherapy is often accompanied by numerous side effects, 
including hair loss, nausea, pain, fatigue (Carelle et al., 2002), and a range of 
psychological effects, such as distress, anxiety and depression (Pandey et al., 
2006). The combination of these side effects can have a severe impact on a 
patient’s daily activities, sexual life, and employment, leading to a significant 
decrease in the quality of both their and their family’s lives (Lorusso et al., 2017). 
The extent and severity of these side effects and their perception by the public is 
such that it is not unheard of for patients to seek alternative, holistic treatments or 
to decline treatment altogether. Notably, in some cases patients are reported to 
decline conventional treatments if they feel that the loss of quality of life is not 
worth what is perceived as a slight increase in survival chance (Frenkel, 2013). 
Further to this, Robb et al. reported almost all participants surveyed in a study 
perceived chemotherapy as “horrible” and the treatment being “almost as bad” as 
the cancer itself (Robb et al., 2014). The balance between developing drugs 
quickly whilst limiting exposure to toxic side effects remains a significant challenge 
in cancer drug development.  
With cancer remaining one of the biggest causes of mortality worldwide, it 
presents a considerable target for researchers and pharmaceutical developers, 
although this interest and its considerable expenditure does not seem to translate 
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into success for the patient - one study found that between 2009 to 2013, over half 
(57%) of European Medicines Agency-approved oncology drugs entered the 
market without clear evidence that they improved patient survival or quality of life 
(Davis et al., 2017). Thus, it is clear that there is still a pressing need to improve 
the effectiveness of modern chemotherapy, and translate clinical trial success into 
improved outcomes for patients.  
 
1.6 | The Mechanisms of Chemotherapy – Apoptosis 
 
There are hundreds of chemotherapy drugs currently available on the 
market. Most can be characterised and grouped according to their molecular 
targets or mechanisms, as briefly detailed in section 1.5. Despite these 
differences, the end result is that the drugs kill cancer cells by initiating a form of 
programmed cell death called apoptosis.  
Apoptosis is a mechanism for the removal of cells that are no longer 
required or damaged cells that pose a threat to the organism. Cells undergoing 
apoptosis display a number of distinct morphological changes: DNA fragmentation, 
cell shrinkage (pyknosis), membrane “blebbing”: which describes the separation of 
the cell into fragments called apoptotic bodies, and finally the translocation of the 
lipid phosphotidylserine from the inner leaflet of the cell membrane to the outside, 
which signals neighbouring cells and nearby macrophages to phagocytise the cell  
(Portt et al., 2011).  
Apoptosis is triggered by one of two pathways; intrinsic: wherein apoptosis 
is triggered in response to cellular stresses, and extrinsic: triggered by signals 
external to the cell (see Figure 8). Both pathways converge on a single “execution” 
pathway: a series of intracellular proteolytic cascading reactions, mediated by a 
group of proteases called caspases. The caspases are a family of endoproteases 
that have a variety of roles in cellular signalling, inflammation, proliferation and 
regeneration, and cell fate determination and differentiation (Shalini et al., 2014). 
The caspases are numbered by function: caspases 2, 9, 8 and 10 are known as 
the initiator caspases, which activate the executioner caspases 3, 6 and 7, which 
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breakdown other proteins, or activate other enzymes that result in the controlled 
destruction of the cell (McIlwain et al., 2015).  
  
Figure 8 | Mechanisms of Apoptosis. Simplified schematics of the intrinsic (left) and extrinsic 
(right) apoptotic pathways. In the intrinsic pathway, cellular stresses activate pro-apoptotic 
proteins such as Bax and Bak to initiate mitochondria outer membrane permeabilisation 
(MOMP). Pro-apoptotic factors (such as cytochrome c) leak from within the mitochondria into 
the cytosol, where they associate with other factors such as apoptotic protease activating factor 
1 (Apaf1) to activate the caspase proteins and trigger the execution phase of apoptosis. In the 
extrinsic pathway, the binding of death ligands (such as TNF-α or FasL) to transmembrane death 




1.6.1 | Extrinsic Apoptosis 
 
The extrinsic apoptosis pathway is initiated by factors external to the cell. 
Spanning the membrane of the cell are protein receptors called the death 
receptors, members of the large tumour necrosis factor family of genes. 
Interactions between death ligands and their corresponding death receptors 
transmit a signal from the surface of the cell to the intracellular apoptosis 
machinery. The best understood mechanisms are the interactions between tumour 
necrosis factor-α (TNF-α) and tumour necrosis factor receptor 1 (TNFR1) (Chen 
and Goeddel, 2002), and between Fas ligand (FasL) and Fas receptor (FasR) 
(Wajant, 2002). In these pathways, the interaction between ligand and receptor 
recruits cytoplasmic proteins: tumour necrosis factor receptor type 1 associated 
death domain protein (TRADD) for the TNF-α/TNFR1 interaction and Fas-
associated protein with death domain (FADD) for the FasL/FasR interaction. The 
adapter proteins in turn associate with procaspase 8, forming the death inducing 
signalling complex (DISC), which activates procaspase 8, triggering the execution 
pathway of apoptosis (Elmore, 2007) (Figure 8).  
 
1.6.2 | Intrinsic Apoptosis 
 
The intrinsic pathway of apoptosis can occur in response to both negative 
and positive signals. Negative signals involve the absence of compounds that 
usually prevent or block apoptosis, whereas examples of positive signals include 
UV radiation, oxidative stress, and viral infection. The pathway is regulated in the 
mitochondria by the B cell CLL/lymphoma (Bcl-2) family of proteins; a large group 
containing both pro- and anti-apoptotic proteins (Green and Llambi, 2015). 
Activation of the pro-apoptotic members in response to cellular stress is thought to 
induce a translocation of the proteins from the cytosol to the OMM, where 
oligomerization interactions form a pore through which apoptosis-inducing factors 
such as cytochrome c, second mitochondria derived activator of caspases/direct 
IAP binding protein with low pl (Smac/DIABLO), mitochondrial serine protease 
(HtrA2/Omi), apoptosis-inducing factor (AIF), and endonuclease G can escape into 
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the cytosol, triggering the caspase cascade and thus the execution pathway to the 
cell’s death (Ouyang et al., 2012) (Figure 8). The regulation and mechanism of this 
pathway is described in more detail in Section 1.6.3.  
 
1.6.3 | Regulation of Apoptosis 
 
Vital for both cell survival and cell death, apoptosis is a carefully regulated 
pathway. In a healthy system, apoptosis clears old or damaged cells and has roles 
in shaping the embryo during development (Haanen and Vermes, 1996). However, 
excessive apoptosis can cause atrophy and is implicit in neurodegenerative 
disorders such as Parkinson’s disease (da Costa and Checler, 2010) and 
Alzheimer’s disease (Nikolaev et al., 2009). Insufficient apoptosis, or an 
insensitivity to apoptotic triggers, is a characteristic hallmark of cancer (Fernald 
and Kurokawa, 2013).  
 
1.6.3.1 | The Bcl-2 Family – Regulators of Apoptosis 
 
The intrinsic pathway of apoptosis is governed by the Bcl-2 family of 
proteins. Their primary area of function is on the OMM, where they control and 
regulate the initiation of mitochondrial outer membrane permeabilisation (MOMP) 
(Kale et al., 2018).  
There are three distinct subgroups in the Bcl-2 family, defined by both their 
role in the apoptotic pathway and the number of Bcl-2 sequence homology (BH) 
domains they possess (Kale et al., 2018): the pro-survival group containing BH 1-3 
domains, the pro-apoptotic effector group containing BH 1-4 domains, and pro-
apoptotic activator group with only the BH3 domain (See Table 4). Bcl-2-
associated protein X (Bax) and Bcl-2 homologous antagonist killer (Bak) are pro-
apoptotic. Upon activation, these BH 1-4 containing proteins are thought to 
oligomerize to form pores in the mitochondria, as part of the MOMP process, 
although the exact mechanism is subject to some debate (Kroemer et al., 2007). In 
a review on the inconsistencies in the current MOMP models, Zamzami & Kroemer 
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point out that Bax activation can also  result in the formation of ion-permeable 
channels in the IMM, which does not result in the loss of matrix proteins (Zamzami 
and Kroemer, 2003), suggesting that there could be missing pieces in the MOMP 
pore complex puzzle, which is further discussed in Section 1.6.4. Performing the 
opposing function are the pro-survival, BH-1-3 containing proteins, including Bcl-2, 
induced myeloid leukaemia cell differentiation protein (Mcl-1), B-cell lymphoma-
extra-large protein (Bcl-XL) and Bcl-2-like protein 2 (Bcl-W). These proteins inhibit 
their pro-apoptotic counterparts, repressing MOMP. Finally, the third subgroup of 
the Bcl-2 family consists of the BH3 only proteins (containing one region of Bcl-2 
sequence homology), which are also pro-apoptotic, but unable to initiate MOMP 
alone. Members of this class include BH3 interacting domain death agonist (Bid), 
Bcl2-like protein 11 (Bim), Bcl-2-associated death promoter (Bad), P53 
upregulated modulator of apoptosis (Puma) and phorbol-12-myristate-13-acetate-
induced protein 1 (Noxa). These proteins are regulated in response to a variety of 
cellular stresses such as DNA damage (Chipuk et al., 2010).  
  
NAME DOMAINS ROLE 
Bcl-2, Bcl-XL, Bcl-w, Mcl1 BH1-3 Pro-survival  
Bax, Bak BH1-4 Pro-apoptotic effectors 
Bim, Bid, PUMA, Bad, Hrk, Bik, 
NOXA 
BH3 Only Pro-apoptotic activators/sensitisers 
Table 4 |The Bcl-2 Family of Proteins.  The Bcl-2 family regulate cell death through interactions 
with the mitochondrial membrane or with each other. These interactions are dictated by the BH 
domains they possess.  
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1.6.4 | Models of MOMP 
 
The full mechanism of MOMP has yet to be universally agreed upon, but it 
is generally thought that it involves the opening or the formation of the 
mitochondrial permeability transition pore (mPTP). The composition of the mPTP 
is again subject to much debate, although the central motif is conserved: the 
release of pro-apoptotic factors from the mitochondria into the cytosol (Suh et al., 
2013).  
The oligomerization of Bax and/or Bak to create a pore through the OMM, 
described in Section 1.6.2, makes up just one of a number of currently proposed 
models (Figure 9). In several of these models VDAC, introduced in Section 1.3.6, 
is a common denominator. Located on the OMM, it serves as a gateway for the 
entry and exit of mitochondrial metabolites (Shoshan-Barmatz et al., 2010). In one 
model, Bax interacts directly with VDAC to create a larger pore in the membrane 
to allow intramembrane apoptotic factors to escape (Shore, 2009). Another, almost 
in direct contrast, suggests that Bid interacts with VDAC to close the channel, 
disrupting mitochondrial ATP/ADP exchange which then causes membrane 
permeablisation through a yet unidentified, alternative mechanism (Rostovtseva et 
al., 2005). Another model proposes the rupture of the OMM altogether, caused by 
a change in the concentration of solutes in the mitochondrial matrix, which in turn 
drives water into the mitochondria, causing it to swell which eventually perturbs the 
OMM. The entry of these low-molecular weight solutes is believed to occur 
through the mPTP, which in this model is thought to consist of VDAC on the OMM, 
adenine nucleotide translocator (ANT) on the IMM, and cyclophilin D in the matrix, 
although its exact composition is again not yet fully determined (Garrido et al., 
2006). Some studies however suggest that VDAC is not essential to MOMP at all. 
For example, experiments have shown that mitochondria lacking all isoforms of 
VDAC (VDAC1, 2 and 3) remain able to undergo the permeability transition, as 
well as Ca2+ and oxidative stress-induced cell death (Baines et al., 2007).    
VDAC plays an additional role in cancer metabolism: protecting cancer cells 
against apoptosis and contributing to the Warburg effect through binding to 
hexokinase (HK). In glycolysis, HK catalyses the ATP-dependent conversion of 
50 
 
glucose to glucose-6-phosphate. The binding of HK to VDAC serves multiple 
purposes that provide a proliferative advantage to cancer cells; by anchoring HK to 
the mitochondria, HK is allowed direct access to mitochondrial ATP, allowing for 
increased enzymatic turnover and thus the high glycolytic flux associated with the 
Warburg effect. HK also competes with the pro-apoptotic Bcl-2 proteins for VDAC 
binding, inhibiting the initiation of apoptosis (Shoshan-Barmatz et al., 2015).      
  
Figure 9 | Mechanisms of MOMP. From left to right: Bax and/or Bak, proapoptotic members 
of the Bcl-2 family, oligomerise into a channel on the outer mitochondrial membrane (OMM). 
Bak/Bak are also thought to interact with VDAC on the OMM to create a larger channel. Influx 
of low molecular weight solutes thorough the permeability transition pore (PTP) can cause the 
mitochondria to take on water, driven by osmotic force. This swelling can lead to the rupture 
of the OMM. Finally, sustained closure of VDAC can disrupt ATP/ADP exchange between the 




1.7 | Priming 
 
Chonghaile et al. showed that a cell’s clinical response to chemotherapeutic 
drugs is dictated by an intrinsic sensitivity to initiate apoptosis (Chonghaile et al., 
2011). The group referred to this as “mitochondrial priming”, whereby the more 
“primed” a cell’s mitochondria are, the more sensitive they are to apoptotic 
triggers. This was tested by introducing BH3-linked peptides derived from pro-
apoptotic Bcl-2 proteins to tumour cells from patients with a range of different 
types of cancer. The experiment measured the response to these peptides, and 
found the cancers that were more “primed” exhibited a greater response to 
chemotherapeutic treatments (Chonghaile et al., 2011).  
If it is possible to manipulate a cell’s apoptotic threshold, priming could 
represent a strategy to improve current chemotherapy regimens, potentially 
leading to lower dosages and reducing side effects experienced by patients. There 
have been a large number of studies on natural and synthetic products which 
appear to have a chemosensitising effect, with some examples highlighted in 
Table 5. Yang et al. found that the plant polyphenol gossypol increased the 
sensitivity of colonic cancer cell lines to the anti-cancer drug 5-Fluorouracil (5-FU) 
through the downregulation of thymidylate synthase, cyclin D1 and the mTOR 
signalling pathways (Yang et al., 2015). Work from Sharma et al. demonstrated 
that treating head and neck cancer cell lines with the flavonol quercetin sensitised 
the cells to the induction of apoptosis by the anti-cancer drug cisplatin (Sharma et 
al., 2005). Other examples include curcumin (Kumar et al., 2016), the dietary 
triterpene lupeol (Liu et al., 2016) and even low doses of gamma-rays (Caney et 
al., 1999). The “sleep hormone” melatonin has been described to possess a 
priming effect, the mechanism for which lies within alterations to mitochondrial 
metabolism (Proietti et al., 2017). A final prominent example is cannabidiol (CBD), 
a non-psychoactive constituent of marijuana. Priming with CBD prior to treatment 
with cisplatin was found to enhance cell death compared to treatment with cisplatin 
alone. This priming effect was attributed to elevated ROS, Ca2+, and changes in 
gene expression, including VDAC, p53 and Nrf2 (Henley, 2015). The table 
represents only a handful of examples; the area of research is rapidly expanding, 
as illustrated in Figure 10.  
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Table 5 |”Priming” in the Literature.  Whilst not exhaustive, this table highlights the use of 





DRUG CANCER MECHANISM REFERENCE 
Lupeol (Combination) 5-Fu Gastric 
Up regulation of Bax 
(Liu et al. 2016) 
Up regulation of p53 
Down regulation Bcl-2 





(El-Senduny et al. 
2015) 
Increase in ROS 
Decrease in Dyrk1B 
Decrease in pERK1/2 
Decrease in pSTAT3 
Quercetin (Primed) Cisplatin Head and Neck 
Decrease in Bcl-2, Bcl-XL (Sharma et al. 




Down regulation of 
thymidylate synthase 
(Yang et al. 2015) Inhibition of mTOR 
signalling pathway 
Cyclin D1 inhibition 
Triptolide 
(Combination) 
Doxorubicin Breast Inhibits MDM2 expression 





Inhibition of DNA 
Methyltransferase 




increased of GAS1, 




Induction of ROS 
(Wang et al. 
2010) 
Decrease in z-VAD 







Gemcitabine Prostate ELK1 Inactivation 




Doxorubicin Breast Enhanced drug delivery 





Reduction of GRP78, 
GRP94 
(Graham et al., 
2016) 
Decrease in AKT 
phosphorylation 
  
Cannabidiol (Primed) Cisplatin Breast 
Increased ROS 
(Henley, 2016) 
Increased calcium levels 














1.8 | Short-Chain Fatty Acids as Potential Priming Agents 
 
Bingham et al. in 2003 revisited the much-debated theory that the 
consumption of dietary fibre protects against the development of colorectal cancer 
(Burkitt, 1971; Shankar and Lanza, 1991; Trock et al., 1990). In a large scale 
observational study they confirmed that dietary fibre was inversely correlated to 
the incidence of colon cancer and concluded that in populations with a low intake 
of fibre, doubling the intake could reduce the risk of colorectal cancer by up to 40% 
(Bingham et al., 2003). Dietary fibre is indigestible to humans and is instead 
fermented in the digestive tract by the resident microbiota. The impact of the 
microbiota on human health is a rapidly growing field of research, and its influence 
has been observed in metabolism (Hansen et al., 2015; Mardinoglu et al., 2015) 
the immune response (Zhang et al., 2015), and behaviour (Desbonnet et al., 2014; 
Kelly et al., 2016).  In the context of dietary fibre, the observed protective effect 
against cancer has been attributed to the production of a group of metabolic 
molecules called the short chain fatty acids (SCFAs) (Gill et al., 2018; Schug et al., 
2016; Wong et al., 2006). 
Figure 10 | Chemosensitisation on PubMed. Increase in the number of “chemosensitivity” 






















































SCFAs are organic fatty acids with an aliphatic tail of 2-6 carbons, although 
typically refers to acetate (2 carbons, C2), propionate (C3) and butyrate (C4) 
(Figure 11). They are produced in in the lumen of the colon by the fermentation of 
indigestible fibre by the gut microbiota, in particular anaerobic bacteroides, 
bifidobacteria, eubacteria,  streptococci, and lactobacilli (Layden et al., 2012), in 
an approximate ratio of 60:20:20 acetate: propionate: butyrate (Morrison and 
Preston, 2016). As a group, they are reported to be a source of energy in the 
colon, and to have regulatory roles in glucose, fatty acid, and cholesterol 
metabolism, appetite and immune regulation, and tumour prevention (den Besten 
et al., 2013). 
 
1.8.1 | Butyrate 
 
Butyrate is the primary energy source for colonic epithelial cells and has 
roles in cell proliferation and differentiation (Perego et al., 2018).  Primarily found 
in the colon, butyrate’s well defined activity as a histone deacetylase (HDAC) 
inhibitor (Ho et al., 2017) has earned it special interest from researchers, being 
implicated in suppressing colonic inflammation (Zimmerman et al., 2012), the 
induction of apoptosis (Maruyama et al., 2012) and autophagy (Jintao Zhang et al., 
2016) in cancer cells. Butyrate has also been shown to stimulate peptide-YY 
production in enteroendocrine cells, a hormone that is thought to regulate appetite, 
an effect again attributed to butyrate’s HDAC inhibitory activity (Larraufie et al., 
2018). Butyrate has also been implicated in regulation of the immune system 
(Corrêa-Oliveira et al., 2016) through the control of regulatory T cells (Smith et al., 
2013) and macrophages (Chang et al., 2014). 
 




1.8.2 | Propionate 
 
Propionate is primarily absorbed by the liver, although its metabolic fate and 
function is not well understood and subject to conflicting reports in humans at 
present due to a lack of data from human studies. For example, propionate  has 
been shown to be both an inhibitor of and a substrate for gluconeogenesis (Wong 
et al., 2006). However, like its counterparts acetate and butyrate, there is evidence 
that propionate has beneficial health effects. In particular, it has been shown that 
propionate can protect against obesity through stimulation of gut hormones (Lin et 
al., 2012), and that long term propionate delivery to the colon prevents increases 
in body weight and can decrease fat accretion (Chambers et al., 2015). Propionate 
has also been shown to reduce plasma cholesterol levels though the 
downregulation of several genes involved in cholesterol synthesis (Alvaro et al., 
2008).  
 
1.8.3 | Acetate 
 
Acetate, as well as being the SCFA produced in the largest quantities, has 
the unique position as a progenitor in a large variety of metabolic pathways (Figure 
11).  The use of acetate in metabolism is almost universally conserved and can be 
traced back to the origins of life (Pandey et al., 2018). Prokaryotes, such as those 
belonging to proteobacteria and cyanobacteria, are known to assimilate acetate to 
replenish metabolites for the TCA cycle (Tang et al., 2011), while lower 
eukaryotes, such as slime moulds, incorporate acetate into lipid biosynthesis 
(Davidoff and Korn, 1963). In humans, whilst the majority of exogenous acetate is 
a by-product of fibre digestion by gut microbiota, it can also enter the body directly 
via the diet, and can be produced through the hydrolysis of acetyl-CoA and 
oxidation of alcohols in the liver, as well as the deacetylation of histones and 
hydrolysis of acetylated metabolites (Schug et al., 2016). The primary fate of 
acetate – its conversion into acetyl CoA – means acetate is incorporated into a 
broad range of metabolic pathways, which can be broadly categorised as energy 
production, the regulation of protein expression, and the biosynthesis of fatty acids 
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and sterols. These are described in greater depth in the Sections that follow and 
illustrated in Figure 12.  
 
1.8.3.1 | Acetate Transport 
  
The mechanisms by which acetate and the other SCFAs are taken up by 
cells, especially cancer cells, have yet to be fully resolved. In the acidic 
environment of the large intestine, acetic acid, a weak acid, is present 
predominately in the anionic form, acetate, to which the cell membrane is 
impermeable. Thus, the majority of exogenous acetate and other SCFAs must 
enter the cell through an active transport mechanism, of which 3 have been 
identified so far (Schug et al., 2016). In the first, acetate transport is bound to the 
export of bicarbonate ions in the colon. In the second, acetate (and the other 
SCFA) transport is mediated by sodium coupled monocarboxylate transporters 
(SMCTs), such as SLC5A8 (Miyauchi et al., 2004). Finally in the third, the 
transport of SCFAs is coupled with H+ through the monocarboxylate protein (Kirat 
and Kato, 2006). 
 
1.8.3.2 | Acetate Metabolism 
 
Inside the cell, the primary fate of acetate is the conversion to acetyl CoA, 
catalysed by 2 enzymes: the mitochondria-bound acetyl-CoA synthetase short-
chain family member 1 (ACSS1) and the nuclear-cytosolic localized associate 
acetyl-CoA synthetase short-chain family member 2 (ACSS2) (Fujino et al., 2001; 
Luong et al., 2000). Acetyl CoA has a unique position as a “central” metabolite, 
siting at the centre of a number of anabolic pathways. In the mitochondria, acetyl 
CoA has roles in ketone body synthesis, protein acetylation, and is a source of 
carbon for the TCA cycle. In the cytosol, ACSS2-derived acetyl CoA is involved in 
fatty acid synthesis, protein acetylation, and steroid synthesis (Pietrocola et al., 
2015). These pathways, particularly fatty acid synthesis, make acetyl CoA a 
compound of special interest in cancer metabolism owing to the increased 
demand of cellular components for rapid proliferation. This is highlighted by the 
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expression of ACSS2 in many cancer cell lines (Comerford et al. 2014). The 
incorporation of acetate into the TCA cycle is also of importance to cancer cell 
metabolism; as the switch from OXPHOS to glycolysis consumes and depletes 
glucose from the tumour microenvironment, acetate-derived acetyl-CoA becomes 
an alternative choice to maintain energy homeostasis (Keenan and Chi, 2015). 
 
1.8.3.3 | Acetate Signalling 
  
On the surface of the cell, acetate and the other SCFAs act as ligands to a 
series of g-protein coupled protein receptors (GPCRs) known as the free fatty Acid 
receptors (FFARs), of which there are 4 known variants: FFAR1, FFAR2, FFAR3 
and FFAR4, also known as GPR40, GPR43, GPR41, and GPR42 respectively 
(Schug et al., 2016). Of the 4, only FFAR2 and FFAR3 bind to and are activated 
by the SCFAs (Brown et al., 2003); FFAR1 and FFAR4 are known to bind medium 
to long-chain fatty acids (C6-C18) (Miyamoto et al., 2016). The affinity and 
expression of the two SCFA-binding receptors varies.  
FFAR2 is expressed in enteroendocrine cells, and binds acetate and 
propionate > butyrate in order of affinity.  
FFAR3 is expressed more broadly; in adipose tissue, in the intestine, and in 
the peripheral nervous system, and binds propionate > butyrate > acetate in order 
of affinity (Miyamoto et al., 2016).  
Binding of acetate to FFAR2, as is the case in typical ligand-GPCR 
interactions, is known to cause an increase in intracellular Ca2+. The physiological 
effects of such interactions are broad and tissue dependent, making FFAR2 a 
potential target in the therapy of a number of malignancies. In pancreatic β-cells, 
FFAR2 interactions have been shown to have a role in insulin production and 
interestingly, expression is altered in insulin resistance (Priyadarshini et al., 2015). 
In adipocytes, FFAR2 binding has been implicated in leptin production, which has 
roles in appetite regulation (Ichimura et al., 2009). Through their interactions with 
the FFAR family, the SCFAs have also been shown to influence immune cell 
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function, including the production of cytokines, the induction of chemotaxis and the 
differentiation of immune cells (Corrêa-Oliveira et al., 2016).  
There have been relatively few studies on the role of the FFAR family in 
cancer. One study implicates FFAR2 in the carcinogenesis of gallbladder cancer 
(Hatanaka et al., 2010) whilst another showed that SCFA exert an antitumorigenic 
effect through FFAR2 interactions, which was found to be lost in colon cancer cell 
lines (Y. Tang et al., 2011).  Such conflicting reports could indicate that the role 
FFARs play in cancer is largely tissue and expression-dependant.  
 
1.8.3.4 | Acetate and Genetic Regulation  
  
Acetate has been shown to modulate genetic expression through two 
mechanisms: increased acetylation of DNA and inhibition of histone deacetylation. 
The histones are proteins that act as spools for DNA strands, condensing and 
packaging DNA into tight structures called nucleosomes.  This condensed state is 
associated with decreased gene expression, prohibiting the access of the genetic 
transcription machinery (Bannister and Kouzarides, 2011). Acetylation of histones, 
catalysed by histone acetyltransferases (HATs) relax the condensed structure, 
allowing for increased gene expression, whereas deacetylation, catalysed by 
histone deacetlyases (HDACs) performs the opposite action (Kuo and Allis, 1998). 
Acetyl CoA is utilized as a substrate for protein acetylation, and so through the 
increased levels of ACSS-derived acetyl CoA, acetate supplementation can affect 
the expression of many different genes (Soliman and Rosenberger, 2011). 
Furthermore, acetate supplementation has been shown to suppress HDAC 
expression directly, a role associated with its anti-proliferative effect in cancer 
(Brody et al., 2017).   
 
1.8.3.5 | Acetate and its Role in Cancer 
  
The evidence presented thus far suggests that acetate has opposing effects 
in cancerous cells. On one hand, acetate is a key substrate to support the 
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Figure 12| The Metabolic Fates of Acetate. Acetate can enter the cell via various active 
transporters, or through passive diffusion in acidic environments. Inside, cytosolic acetate is 
converted to acetyl CoA via ACSS2, which then feeds into a range of catabolic pathways. In the 
mitochondria, the conversion of acetate to acetyl CoA is catalysed by ACSS1, which then enters 
the tricarboxylic acid cycle. In addition, acetate can interact with FFAR2 or FFAR3 on the 
surface of the cell, trigging signals that modulate various metabolic pathways, such as appetite 
regulation, immune cell regulation, and the production of leptin.  
biosynthetic and energetic needs of a rapidly proliferating tumour, and on the 
other, demonstrates anti-tumorigenic properties through signalling or epigenetic 
pathways. Further to this, some studies also implicate acetate in directly inducing 
apoptosis in a number of cell types (Emenaker et al., 2001; Marques et al., 2013; 
Oliveira et al., 2015). These conflicting reports may be as a result of the many 
ways acetate can enter the cell and affect various signalling and metabolic 
pathways, demonstrating the complexity of the interactions between acetate and 




1.9 | Aims 
 
Whilst advances in the knowledge of cancer have led to improvements in 
the effectiveness of treatment; side effects and the risk of deadly recurrence still 
present significant problems for those diagnosed. However, recent renewed 
interest in the cell’s mitochondria and how these organelles play a vital role in 
supporting cancer cell metabolism may provide an opportunity to exploit these 
organelles to further refine the effectiveness of treatment. Stressing the 
mitochondria may provide a mechanism to improve a cancer cell’s proximity to 
drug-induced apoptosis – to prime cancer cells for death. Although numerous 
methods exist to stress cells, the difficulty in finding a suitable agent parallels the 
challenges in cancer chemotherapy – targeting cancer cells whilst avoiding or 
limiting cytotoxicity to healthy cells.  
With the recent interest in the SCFAs, I have identified a potential priming 
agent in acetate, the shortest of the SCFAs. As a group, the SCFAs, natural by-
products of diet, have been documented to have roles in prevention of colorectal 
cancer, and preliminary work by my group, has shown that acetate exhibits anti-
proliferative effects on cancer cells in vitro, whilst having no significant effect on 
non-cancerous cell lines (Henley, 2015; Sahuri Arisoylu and Bell, 2016). To take 
these findings forward, the aim of this project was to investigate the potential of 
acetate as a priming agent. To address this aim, the project attempted to answer 2 
broad questions:  
1.) How does acetate affect cells? 
2.) Can acetate prime cancer cells for death? 
As described, acetate has wide-ranging effects on cells. This study was 
designed to clarify the effects acetate has on cancer cells, with a particular focus 
on mitochondrial metabolism, as not only are the mitochondria central to 
chemotherapy-induced apoptosis, but the documented effects of SCFAs on 
mitochondria are relatively sparse. To this end I measured several key markers of 
mitochondrial stress, including ROS, Ca2+, morphology, and respiration, and 
investigated the effect of acetate on overall cell viability and induction of apoptosis. 
Following this, I investigated the effect that priming – the treatment of cells with 
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acetate prior to treatment with an anticancer drug – has on apoptosis and cell 
viability compared to simultaneous treatment with the drug and acetate, and to 
drug treatment alone.  
To answer the questions set out I have selected 2 cancer lines: HCT116 
(human colon cancer) and MCF7 (human breast cancer), and a non-cancerous 
cell line MCF10A (“healthy” breast tissue), as controlled, replicable models to 
identify the effects of acetate. The selection of cancer cell lines allows me to study 
the effects of acetate in both tissues that model areas close to and away from the 
site of acetate production (colon and breast respectively). In addition, MCF7 was 
used in previous work which examined mitochondrial priming with cannabidiol 
(CBD) prior to treatment with cisplatin, which has provided a starting point in 
designing the protocols used for this project (Henley, 2015). Finally, MCF10A, the 
non-cancerous cell line, was used to ensure that any priming effects caused by 
acetate are confined to cancer lines. 
 
1.10 | Hypothesis 
  




2.0 | Materials & Methods             
2.1 | Cell Lines 
 
2.1.1 | HCT116 
 
HCT116 is an adherent, human epithelial cancer cell line derived from 
colorectal carcinoma (Brattain et al., 1981). HCT116 cells were cultured in Roswell 
Park Memorial Institute medium (RPMI-1640) (Thermoscientific, UK), 
supplemented with 10% fetal bovine serum (FBS) (Sigma, UK), 1% l-glutamine 
(Thermoscientific, UK) and 1% penicillin/streptomycin (Thermoscientific, UK). 
HCT116 cells were a gift from Dr N. Navaratnam (Medical Research Council, 
Clinical Sciences Centre).   
 
2.1.2 | MCF7 
 
MCF7 is an adherent, human epithelial cancer cell line derived from a 
metastatic mammary adenocarcinoma (Soule et al., 1973). MCF7 cells were 
cultured in Minimum Essential Media (MEM) (Sigma, UK), supplemented with 10% 
FBS, 1% l-glutamine and 1% penicillin/streptomycin. MCF7 cells were a gift from 
Dr. N. Haiji (Imperial College London). 
 
2.1.3 | MCF10A 
 
MCF10A is an adherent, human epithelial non-cancerous breast cell line 
derived from fibrocystic mammary tissue. Non-cancerous, MCF10A was found to 
exhibit spontaneous immortality after culture in low-calcium media (Soule et al., 
1990). MCF10A cells were cultured in a mixture of Dulbecco’s Modified Eagle’s 
Media and Ham’s F12 nutrient mix (DMEM:F12) (Life Sciences, UK), 
supplemented with 5% horse serum (Sigma, UK), 1% penicillin/streptomycin, 20 
ng/mL epidermal growth factor (Sigma, UK), 0.5 mg/mL hydrocortisone (Sigma, 
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UK), 100 ng/mL cholera toxin (Sigma, UK) and 10 µg/mL insulin (Sigma, UK).  
MCF10A cells were a gift from Dr. N. Haiji (Imperial College London). 
 
2.2 | Cell Culture 
 
All work with cell lines was carried out in a laminar flow hood with aseptic 
technique. Cells were grown in sterile T75 or T175 flasks, stored in a humidified 
37°C 5% CO2 incubator, and passaged at around 80% confluency, based on 
visual inspection. For passage, media was removed from cells, and washed with 
sterile phosphate-buffered saline (PBS). Cells were then detached from the 
surface of the flask by incubating with 1-2 mL TrypLE (ThermoFisher, UK) or 
trypsin (Sigma, UK) for MCF10A cells for 7 mins. Following detachment, cells were 
resuspended in fresh media and diluted into new flasks. Cells were only used for 
experimentation between passage 5 and 25, and periodically tested for 
mycoplasma infection using the PlasmoTest Mycoplasma Detection Kit 
(InvivoGen, UK). For seeding cells for experimentation, cells were detached as 
described above, counted using a haemocytometer, and added to wells with the 
appropriate volume of media for the plate being used (100 µL total for 96 well 
plates and initial SeaHorse 24 well plate seeding, 2000 µL for 6 well plates). 
 
2.3 | Reagents 
 
Sodium acetate (Sigma, UK) was dissolved in autoclaved deionized (DI) 
water to make stock concentrations of 1 M and 100 mM. Acetate was diluted to 
working concentrations on the day of the experiment in fresh media. DDP 
(Cisplatin) (Sigma, UK) was dissolved in dimethylformamide (DMF) (Sigma, UK) to 
a stock concentration of 10 mM. DDP was diluted for experimentation on the day 




2.4 | Cell Viability 
 
Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay kit (Sigma, UK). The assay is based on 
the conversion of MTT (yellow) to formazan (purple) by NADPH-dependent 
reductases in the cell (Mosmann, 1983). Cells were seeded onto 96 well plates at 
3x104 cells per well. The assay was performed as per manufacturer’s 
recommendations. Following treatment, cells were washed with PBS and media 
was replaced with phenol red-free media. 10 µL MTT solution was then added to 
each well, and incubated at 37°C 5% CO2 for 3 hours. Media was removed, and 
resultant crystals dissolved in 100 µL MTT solvent. Plates were shaken for 5 mins. 
Viability was then quantified by UV-Vis spectrometry with a microplate reader 
(SPECTROstar Nano, BMG Labtech, Germany). Absorbance at 690 nm was 
subtracted from absorbance at 570 nm. Cell viability presented as percentage of 
the untreated negative control.  
 
2.5 | Bradford Protein Assay 
  
The Bradford Assay, a simple colorimetric assay for total protein 
quantification, was used to quantify cell number following treatment. 
Following completion of the assay, each well was washed twice with ice 
cold PBS. Cells were then lysed with ice cold radioimmunoprecipitation assay 
(RIPA) buffer (Sigma, UK) for 15 minutes on a shaker. Each well was then 
scraped using sterile cell scrapers, and its contents transferred to individual 
Eppendorf tubes, which were cooled on ice. Tubes were then centrifuged at 
16,100 g for 15 mins at 4°C. The supernatant was removed and placed into a new 
set of tubes. 5 µL of each sample was added to the wells of a 96-well plate in 
triplicate. 200 µl Bradford Reagent (BioRad, UK) was then added to each well, and 
absorbance at 595 nm was quantified with a plate reader. A series of protein 
standards (Bovine serum albumin (BSA), BioRad, UK) was used to create a 




2.6 | Detection and Quantification of Apoptosis in Response to Acetate 
Treatment 
 
The induction of apoptosis was measured using the Annexin V-
FITC/propidium iodide (PI) staining kit (Abcam, US) via flow cytometry. The assay 
is based on the translocation of the phospholipid phosphatidylserine (PS) from the 
inner to outer surface of the cellular membrane during apoptosis. Annexin V, a 
protein with high affinity for PS, allows for detection of this event when conjugated 
to a fluorophore, in this case fluorescein isothiocyanate (FITC). PI is a membrane 
impermeable stain which fluoresces when bound to DNA, allowing for the 
distinction between late and early apoptosis, as well as necrotic events (Schutte et 
al., 1998). Each cell line was seeded on 6 well plates at densities of 1.5x105 cells 
per well and treated with media or 10 mM acetate for 24 hours. The assay was 
performed as per manufacturer’s instructions. Following treatment, cells were 
washed once with PBS, detached with 200 µL TrypLE, resuspended in 800 µL 
fresh media, and centrifuged at 1000 g for 5 mins.  The resultant pellet was then 
resuspended in 500 µL supplied binding buffer. Cells were then stained with 5 µL 
Annexin-FITC and/or 5 µL PI for 5 minutes before analysis with flow cytometry 
(Cyan ADP, DaktoCytomation).  
Cells were gated on software (Summit 4.3, DaktoCytomation) to manually 
exclude cellular debris using a plot of forward scatter (FSC) vs side Scatter (SSC). 
Fluorescence of an unstained control was used to set voltage and gain of 
fluorescence channel 1 (FL1, green, for Annexin V-FITC) and fluorescence 
channel 2 (FL2, red, for PI) so the background signal was within the 1st log 
decade. To correct the spectral overlap of the emission spectra of the 2 
fluorophores, single stained controls were set up to allow for manual 
compensation. Stains were considered correctly compensated when the median 
fluorescent intensity (MFI) in each quadrant for missing stain was equal to or 
within 1. The percentage of events in the 4 quadrants (see Table 4) of the FITC 





Table 6|Interpretation of Annexin V-FITC Assay Data. Classification of flow cytometry events 
based on the combination of signal intensities, interpreted by their location on the dot plot 
produced.  The percentage of events in quadrants 2 and 3 (in bold) were combined to 







2.7 | Detection and Quantification of Autophagy 
  
Autophagy was detected using the Autophagy Detection Kit from Abcam 
(ab139484, Abcam, UK). The kit utilizes a propriety fluorescent probe to stain 
autophagic lysosomes and vacuoles. Cells were seeded on 6 well plates at 
densities of 1.5x105 cells per well. Following treatment, cells were washed with 
PBS and harvested with TrypLE. After being quenched with media, cells were 
centrifuged at 1000 g for 5 mins. The resulting pellets were resuspended in 250 µL 
phenol-red free media, to which 250 µL green detection regent was added. 
Samples were incubated for 30 mins at 37°C 5% CO2. Following incubation, cells 
were centrifuged at 1000 g for 5 mins. Pellets were then resuspended in 1X 
supplied Assay buffer, and analysed via flow cytometry. Cells were gated manually 
on software (Summit 4.3) to exclude debris or cellular aggregates using a plot of 
FSC vs SSC. Data was collected in FL1 and the MFI recorded.   
  
ANNEXIN V-FITC PI QUADRANT CLASSIFICATION 
- - 1 (Lower left) Healthy 
+ - 2 (Lower Right) Early Apoptotic 
+ + 3 (Upper Right) Late Apoptotic 
- + 4 (Upper left) Necrotic 
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2.8 | SeaHorse MitoStress Assay 
 
Changes in mitochondrial respiration were monitored using the SeaHorse 
XFe24 Flux Analyser (Agilent, USA) to carry out the SeaHorse MitoStress Assay 
according to manufacturer specifications. 3.0x104 cells per well were seeded on 
supplied SeaHorse 24 well plates. Cells were initially seeded in 100 µL media, to 
followed by a further 150 µL media was added once the cells had adhered (3-4 
hours, based on visual inspection). Cells were then treated with 10 mM acetate or 
media for 24 hours (working volume of 500 µL per well). Supplied SeaHorse Media 
(Aglient, USA) was supplemented with glucose and sodium pyruvate to final 
concentrations of 1 g/L and 1 mM respectively, adjusted to pH 7.4 and filter 
sterilised before use. Following treatment, cells were washed twice with SeaHorse 
media and incubated for 1 hour at 37°C with no CO2. 
The assay itself consists of the measurement of the oxygen consumption 
rate (OCR) in real time prior to and after the injection of 3 known mitochondria-
affecting drugs to obtain the parameters described in Table 7: 
1.) Oligomycin (Sigma, UK), an ATP Synthase inhibitor which allows 
quantification of OCR dedicated to ATP production. 
2.) Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) 
(Sigma, UK), an uncoupling agent which allows measurements of a 
cell’s maximum respiration rate. 
3.) Antimycin A (Sigma, UK) and rotenone (Sigma, UK), Complex I and 
II inhibitors which allow the determination of the basal rate of 
respiration. The combination of drugs also allows the calculation of the 
OCR associated with proton leak, non-mitochondrial respiration, and 







Table 7 | Interpretation of SeaHorse MitoStress Assay Data. Description of mitochondrial 
respiration parameter calculations, as performed by the MitoStress Test Report Generator. 
Drug concentrations were optimised individually for each cell line to ensure 
oligomycin and FCCP injections were causing the maximum decrease and 
increase in OCR. The data was acquired in cycles as follows: Mix: 3 mins, Wait: 2 
mins, Measure: 3 mins, as per the manufacturer’s instructions. Three 
Mix/Wait/Measure cycles were performed at the start of the assay, and after each 
injection. A typical MitoStress assay output is shown in Figure 13.  




Minimum rate measurement after Rotenone/antimycin injection 
Basal 
Respiration 




(Maximum rate measurement after FCCP injection)-(Non-mitochondrial 
respiration) 
Proton Leak 




(Last rate measurement before injection of oligomycin)-(Minimum rate 




(Maximal Respiration)-(Basal respiration)  
Figure 13 | The SeaHorse MitoStress Assay. Schematic showing a typical SeaHorse 
MitoStress Assay profile, and how the OCR levels can be interpreted in response to the 
injection of Oligomycin, FCCP, and Rotenone & antimycin A. Image from Agilent 
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2.9 | Detection & Quantification of  Cellular ROS. 
 
The 2’,7’–dichlorofluorescin diacetate (DCFDA) assay was used to detect 
changes in the levels of ROS. The presence of ROS in the cell converts DCFDA 
into the highly fluorescent compound 2’,7’–dichlorofluorescin (DCF) (Keston and 
Brandt, 1965; LeBel et al., 1992). Cells were seeded on black-walled 96 well 
plates at 2.5x104 cells per well. Following treatment, cells were washed with PBS 
and incubated with 20 µM DCFDA (Sigma, UK) at 37°C 5% CO2 in the dark for 45 
mins. The contents of the well were aspirated from the cells, and replaced with 
100 µL PBS per well. Fluorescence induced by ROS was quantified by 
fluorescence spectroscopy (Excitation 485 nm, Emission 535 nm) (FLUOstar 
Optima, BMG Labtech, Germany).  
 
2.10 | Detection and Quantification of Intracellular Ca2+ 
 
The Fluo-4 Direct Calcium Assay (Invitrogen, UK) was used to detect 
changes in total intracellular Ca2+ levels (Gee et al., 2000). Cells were seeded on 
black-walled 96 well plates at 2.5x104 cells per well. The assay was performed 
according to manufacturer’s specifications (Invitrogen, 2011). Following treatment, 
100 µL 2X Fluo-4 Direct calcium assay reagent was added to each well. Cells 
were then incubated for 30 mins at 37°C 5% CO2 in the dark. Changes in Ca2+ 
were then quantified by fluorescence spectroscopy (Excitation 494 nm, Emission 





2.11 | Observation & Quantification of Mitochondrial Morphology. 
 
2.11.1 | Observation of Mitochondrial Morphology by Confocal Microscopy  
 
The MitoTracker Deep Red stain was used to observe and quantity 
changes in mitochondrial morphology. Cells were seeded on 6 well plates at 
1.5x105 cells per well. Following treatment, cells were washed once with PBS and 
stained with 100 nM MitoTracker Deep Red (Thermofisher, UK) for 30 mins at 
37°C 5% CO2 in phenol red-free media. The Lecia SP2 (Leica Microsystems, 
Germany) was used to obtain images, using a HCZ APO L 63X 0.90 NA objective 
lens. After gain and offset adjustments, cells were observed with a 2X digital zoom 
at 2048x2048 formats, 8X line averaging. Three images in different regions of the 
well were collected per treatment condition.  
 
2.11.2 | Analysis of MitoTracker Deep Red Images 
 
The Yeast_Mitomap/MitoLOC plugin for FIJI (Fiji Is just ImageJ, version 
1.6) was used to analyse mitochondrial images from confocal microscopy 
(available from http://www.gurdon.cam.ac.uk/stafflinks/downloadspublic/imaging-
plugins). The plugin defines mitochondria in a region of interest manually drawn by 
the user (Figure 14) and calculates the number of mitochondria, volume, area and 
six shape descriptors including; “compactness”, “distribution isotropy”, 
“isoperimetric quotient”, and “sphericity”, as calculated by Vowinckel et al. 
(Vowinckel et al., 2015). To select cells for analysis, viable cells visible in each 
image were assigned a number. Three numbers in the range were selected at 
random using the Microsoft Excel formula =RANDBETWEEN(1,x), where x is the 
total number of mitochondria in the image. The average measurements of all 















2.11.3 | Flow Cytometric Quantification of Mitochondrial Morphology 
 
As an alternative method to quantify mitochondrial morphology, MitoTracker 
Deep Red stained cells were analysed by flow cytometry. This approach was used 
by Tailor et al. to investigate the effects of butyrate on mitochondrial mass (Tailor 
et al., 2014), based on protocols developed by  Tal et al. (Tal et al., 2009). Cells 
were grown in 6 well plates and treated with media or 10 mM acetate for 24 hours. 
On the day of the assay, cells were washed once with PBS and stained with 100 
nM MitoTracker Deep Red for 30 mins at 37°C 5% CO2. Cells were then washed 
with PBS, detached and harvested, before being resuspended in 500 L PBS. 
Cells were then analysed by flow cytometry (Cyan ADP, Beckman Coulter, USA), 
measuring signal intensity in FL2 (MitoTracker Deep Red). 
 
2.12 | Cell Cycle Analysis 
  
Changes in cell cycle stage were measured with PI staining and flow 
cytometry (Krishan, 1975).  Cells were seeded on 6 well plates at 2.0x105 cells per 
well. Following treatment, cells were washed with PBS and detached with TrypLE. 
Cells were then harvested, centrifuged at 1000 g for 5 min, washed with PBS, and 
Figure 14 | The MitoLOC Plugin for ImageJ. Example images illustrating how the 
Yeast_Mitomap/MitoLOC FIJI plugin can be used analyse mitochondrial morphology. The left 
image is a typical image acquired following MitoTracker treatment. On the right, a region of 
interest is drawn around the cell (purple line). MitoLOC then counts and measures the 
mitochondria, indicated by the pink outlines with numbering 
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centrifuged again at 1000 g for 5 mins. Pellets were then resuspended in 300 µL 
ice cold PBS, followed by the drop-wise addition of 700 µL ice cold 100% ethanol. 
Samples were incubated at -20°C for at least 2 hours. Following incubation, 
samples were centrifuged at 2000 g for 5 mins, and resuspended in 500 L 
fluorescence-activated cell sorting (FACS) buffer. Cells were pelleted once more, 
and to each pellet, 50 µL 100 µg/mL RNAase was added, followed by 450 µL of 50 
µg/mL PI solution. Samples were incubated in the dark for 15 mins at room 
temperature. Following this incubation, cell cycle stage was observed by flow 
cytometry measuring signal intensity in FL2. Debris and cellular aggregates were 
manually excluded using plots of FSC vs SSC. Doublets (single events that 
actually consist of 2 particles) in cell cycle analysis can produce false positives 
and so were manually excluded using a plot of FSC-A vs pulse width.   
 
2.13 | Quantitative Real-Time Polymerase Chain Reaction Analysis 
 
For gene expression quantification, quantitative real time-polymerase chain 
reaction (qRT-PCR) was carried out. Cells were seeded in individual T75 flasks at 
densities of 5x106 cells per flask. Following treatment, messenger ribonucleic acid 
((RNA)(mRNA)) was isolated from the treated cells using the Qiagen RNeasy kit 
(Qiagen, UK). The kit was used as instructed and the samples were quantitated to 
1 μg/μL using the NanoDrop 1000 (ThermoScientific, UK) to normalise RNA 
amount. Complementary deoxyribonucleic acid (cDNA) synthesis was carried out 
according to the Thermoscript™ RT-PCR Systems protocol (Invitrogen, UK) using 
the oligo(dT)20 primer method with an incubation at 50°C for 60 minutes. The 
reaction was terminated by incubating at 85 °C for 5 minutes. qPCR was carried 
out in accordance to TaqMan® Universal Master Mix II, no UNG (uracil-DNA 
glycosylases) for primers in Table 8. The 96 well plate was placed in a preheated 
Applied Biosystems 7500 Fast Real-Time PCR System instrument and run at a 
cycling program of 50°C for 2 minutes, 95°C for 2 minutes, 45 cycles of 95°C for 
15 seconds followed by 56°C for 30 seconds, then a dissociation confirmation 
step. Any samples that read < 0.1 cycle threshold (Ct) were removed for quality 
control purposes. Results were calculated using the ΔΔCt method as described by 
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Bookout et al. (Bookout et al., 2006). Samples were normalised to the 











GENE ASSAY ID 
Voltage Dependent Anion Channel 1 
(VDAC1) 
Hs01631624_gH 
P53  Hs01034249_m1 
Nrf2 Hs00232352_m1 
Acetyl-coenzyme A synthetase short-
chain 1 (ACSS1)  
Hs00287264_m1 
Acetyl-coenzyme A synthetase short-
chain 2 (ACSS2) 
Hs00218766_m1 
β-Actin Hs01060665_g1 
Table 8 | Taqman Probes Used In Gene Expression Analysis.  
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2.14 | SeaHorse GlycoStress Test 
  
The short term effects of acetate on glycolysis were measured using the 
SeaHorse GlycoStress Test (Aglient, UK) on the SeaHorse XFe24 Flux Analyser 
(Agilent, USA). Cells were initially seeded in 100 µL media at densities of 3.0x104 
cells per well, to which a further 150 µL media was added once the cells had 
adhered (3-4 hours, based on visual inspection). Supplied SeaHorse Base Media 
(Aglient, USA) was supplemented with 1% l-glutamine, adjusted to pH 7.4 and 
filter sterilised before use. Following treatment, cells were washed twice with 
SeaHorse media and incubated for 1 hour at 37°C with no CO2. The assay itself 
consists of the measurement of the extracellular acidification rate (ECAR) in real 
time prior to and after the injection of 3 known metabolic drugs to obtain the 
parameters described in Table 9 (See Figure 15);  
1.) Glucose (Sigma, UK), triggering a glycolytic response as cells utilize 
the injected glucose (Final concentration: 10 mM) 
2.) Oligomycin (Sigma, UK), an ATP Synthase inhibitor, inhibiting 
oxidative phosphorylation, shifting the cell’s energy production to 
glycolysis and revealing the cells maximum glycolytic capacity. (Final 
concentrations: 2 µg/mL in MCF10A, 1 µg/mL in HCT116 and MCF7) 
3.) 2-deoxy-glucose (2-DG) (Sigma, UK), which inhibits glycolysis 
through competitive binding to glucose hexokinase, the first enzyme 
in the glycolytic pathway (Final concentration: 50 mM).   
 
Seeding densities and drug concentrations were optimised individually for 
each cell line. The data was acquired in cycles as follows: Mix: 3 mins, Wait: 2 
mins, Measure: 3 mins, as per the manufacturer’s instructions. 3 
Mix/Wait/Measure cycles were performed at the start of the assay, and after each 
injection. To measure the short-term effects of acetate, either media or acetate 





Table 9 | Interpretation of SeaHorse GlycoStress Assay Data. Description of glycolytic parameter 
calculations, as performed by the GlyoStress Test Report Generator. 
  
PARAMETER RATE MEASUREMENT EQUATION 
Glycolysis 
(Maximum rate measurement before oligomycin injection)-(Last reate 
measurement before glucose injection) 
Glycolytic Capacity 
(Maximum rate measurement after oligomycin injection)-(Last rate 
measurement before glucose injection).  
Glycolytic Reserve (Glycolytic Capacity)-(Glycolysis) 
Non-Glycolytic 
Acidifcation 
Last rate measurement prior to glucose injection 
Figure 15 | The SeaHorse GlycoStress Assay. Schematic showing a typical SeaHorse GlycoStress 
Assay profile, and how the ECAR levels can be interpreted in response to the injection of 
glucose, oligomycin, and 2-DG. Image from Agilent 
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2.15 | Acute OXPHOS Measurements 
  
The short term effects of acetate on OXPHOS were measured using the 
SeaHorse XFe24 Flux Analyser (Agilent, USA). Cells were initially seeded in 100 
µL media at densities of 3.0x104 cells per well, to which a further 150 µL media 
was added once the cells had adhered (3-4 hours, based on visual inspection). 
Supplied SeaHorse Media (Aglient, USA) was supplemented with glucose and 
sodium pyruvate to final concentrations of 1 g/L and 1 mM respectively, adjusted 
to pH 7.4 and filter sterilised before use. Following treatment, cells were washed 
twice with SeaHorse media and incubated for 1 hour at 37°C with no CO2. OCR 
was then measured over the course of 12 hours. To investigate the effect of 
acetate, acetate (to a final concentration of 10 mM) or media (as a control) was 
injected following a basal measurement period of 16 minutes.  
 
2.16 | Acute Intracellular Ca2+ Measurements 
 
The short term effects of acetate on intracellular Ca2+ levels were measured 
with the Fluo4 Direct Calcium Probe (Invitrogen, UK, see section 2.9) using the 
BMG NOVOstar fluorescence plate reader (BMG Labtech, Germany). HCT116 
(2.5x104 cells per well), MCF7 and MCF10A (3.0x104 cells per well) cells were 
seeded on 96 well black plates and allowed to adhere overnight. Media was then 
removed from cells, and replaced with 50 µL Opti-MEM reduced serum media 
(ThermoFisher, UK) (Based on work by Miletta et al. observing the effects of 
butyrate on intracellular Ca2+ (Miletta et al., 2014)) and incubated for 1 hour at 
37°C 5% CO2. Following incubation, 50 µL 2X Fluo-4 Direct calcium assay reagent 
was added to each well, and incubated in the dark for 30 minutes at 37°C 5% CO2. 
Changes in Ca2+ were then quantified by fluorescence spectroscopy (Excitation 
494 nm, Emission 516 nm). Baseline fluorescence was measured for 8 seconds at 
1.46 second intervals. At 15 seconds, 11 µL PBS (control) or 100 mM acetate 
(final concentration: 10 mM) was injected into relevant wells, and fluorescence 




Table 10 | Treatment protocols for priming experiments. 
2.17 | Priming Treatment Protocols 
 
For “priming” treatments, cells were treated for 24 hours with 1, 5 or 10 mM 
acetate, followed by 24 hour treatment with 100 µM DDP after washing with PBS. 
In DDP only treatments, cells were treated with fresh media for 24 hours, followed 
by 24 hour treatment with 100 µM DDP. In “Combination” treatments, cells were 
treated with fresh media for 24 hours, followed by 24 hour treatment with 10 mM 
acetate and 100 µM DDP administered simultaneously (See Table 10). Vehicle 





2.18 | Cell Viability in Response to Priming 
 
The MTT Assay (See Section 2.4) was used to measure cell viability in 
response to priming treatments. Cells were seeded at 3.0x104 cells per well on 96 
well plates and treated as per Section 2.17. The MTT assay was then performed 
as per Section 2.4. 
2.19 | Induction of Apoptosis in Response to Priming 
  
The Annexin V-FITC PI assay (See Section 2.6) was used to measure 
apoptosis induction in response to priming treatments. Cells were seeded at 
1.5x105 cells on 6 well plates and treated as per Section 2.17. The Annexin V-










DAY 1 Media/Vehicle Media/Vehicle 
1,5 or 10 mM 
Acetate 
Media/Vehicle 
DAY 2 Media/Vehicle 100 µM DDP 100 µM DDP 
10 mM Acetate 
+ 100 µM DDP 
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2.20 | 2-Photon Fluorescence Lifetime Imaging Microscopy 
  
2-Photon Fluorescence Lifetime Imaging Microscopy (2P-FLIM) was used 
to image and quantify NADH lifetime decay as a measure of cellular and 
mitochondrial metabolism. This work was carried out in collaboration with 
Professor Stan Botchway at the Rutherford Appleton Laboratory, Harwell. The 
background and merits of this technique are described in detail in Section 5. MCF7 
cells were seeded in individual ibidi dishes at densities of 1.2-1.5x105 cells per 
dish. Cells were treated with DMSO, 10 mM acetate, or 25 mM acetate for 24 
hours. Before imaging, cells were allowed 15 mins to acclimatise to room temp.  
 FLIM images were obtained as follows: 2 photon (690 nm) wavelength light 
was generated by a mode-locked titanium sapphire laser (Coherent Laser Co), 
producing 180 fs pulses at 75 MHz. This laser was pumped by a solid state 
continuous wave 532 nm laser. Images were collected through a water immersion 
60 X 1.2 numerical aperture objective on a modified Nikon TE2000-U confocal 
microscope. Emission was collected with an external fast microchannel plate PMT 
(R3809-U, Hamamastu, Japan), linked to a time correlated single photon counting 
(TCSPC) module (SPC830, Becker and Hickl, Germany). Lifetime calculations and 





2.21 | Statistical Analysis 
 
All statistical analyses were performed on GraphPad Prism 5.04 (San 
Diego, USA). Differences between 2 means were analysed by Student’s Unpaired 
T Test. Means were considered significantly different when p <0.05. Differences 
between groups (>2) of means were analysed by One-Way ANOVA, followed by 
Tukey’s Multiple Comparison Test to investigate specific pair-wise differences. 
Differences between all means in an experiment were considered significantly 
different when p <0.05. Differences between individual means in an experiment 
were considered significantly different when adjusted p <0.05. Calculations of 
concentration in samples were interpolated from a standard curve using a linear 
regression.   
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3.0 | The Effects of Acetate on 
Cells                                               
   
The objective of this chapter was to determine the effect, if any, acetate had 
on the selected cell lines. In Section 1.8.3 it was noted that whilst the effects of the 
SCFAs as a group on cells being broadly documented, the effects of acetate alone 
remains relatively unstudied, particularly with regard to its effect on the cell’s 
mitochondria. Furthermore, published studies on acetate and mitochondria usually 
pertain to acetate as a product of cellular catabolism, rather than exogenous 
sources of acetate, e.g. following the consumption of dietary fibre. 
The effect of SCFAs as a group on apoptosis has been previously 
investigated, but with the majority of the work focused on either combinations of 
SCFAs, or on butyrate alone. Jan et al. reported that “propionibacterial SCFA” 
induces apoptosis in HT29 and CaCo2 cell lines, although the work did not report 
the effects of acetate alone, as the authors used mixes of propionate and acetate 
with ratios ranging from 2.5:1 and 2.9:1 propionate: acetate (Jan et al., 2002).  
Marques et al. observed that acetate induces apoptosis in HCT-15 and RKO 
colorectal cancer (CRC) cell lines, but at much higher concentrations than used in 
this study (70 and 110 mM) (Marques et al., 2013).  In another study, Comalada et 
al. noted that out of the 3 main SCFA (acetate, propionate and butyrate), butyrate 
alone induces cell death (Comalada et al., 2006).  
The effect of the SCFA on cellular metabolism trends toward investigations 
into diet and the inflammatory response, and again predominately focus on 
butyrate. For example, increases in Ca2+ have been observed after treatment with 
5 mM butyrate in rat pituitary cells (Miletta et al., 2014) and after treatment with 1 
mM acetate or propionate in L cells (a component of the entereoendocrine system) 
(Tolhurst et al., 2012). Increased production of ROS has also been reported in 
bone marrow neutrophils in response to treatment with 1-30 mM acetate 




The concentrations of acetate used in this study were selected based on a 
combination of existing literature reporting SCFA concentrations in the body as 
well as concentrations of acetate used both in existing publications and preliminary 
studies. In the literature, there are a wide variety of reported SCFA concentrations, 
which all depend on from where the sample is taken and how long after a meal. 
Louis et al. state that in the colon, the SCFA have a combined concentration that 
varies from 50-150 mM, in a ratio of 3:1:1 acetate: propionate: butyrate, putting 
acetate at concentration of 30 – 90 mM  (Louis et al., 2014). In circulation, acetate 
has been reported at concentrations of 0.258-0.268 mM in the portal vein, 0.115-
0.220 mM in the hepatic vein, and 0.07-0.173 mM in the peripheral circulation 
(Bloemen et al., 2009; Cummings et al., 1987). Studies investigating the effect of 
acetate on cancer in vivo use concentrations ranging from 6.13 mM (Brody et al., 
2017), to 140 mM (Marques et al., 2013). To keep within physiological ranges, and 
to be consistent with doses used on other studies, it was therefore decided to use 
doses ranging from 1-25 mM in this project, with a particular focus on 10 mM, 
which would become the dose used to “prime” cells. 
The objectives in this chapter were therefore as follows: 
1. Investigate the effects of the SCFA acetate on cell viability and 
programmed cell death 





3.1 | The Effects of Acetate on Cell Viability 
  
The MTT cell viability assay was used to investigate the effect a range of 
acetate concentrations had on cell viability (Figure 16).  
In each cell line tested, acetate had no significant effect on cellular viability 








Figure 16 | The Effect of Acetate on Cell Viability. Bars represent mean ±SEM cellular viability 
as a percentage of the untreated control (dashed horizontal line) from n = 5 individual 
experiments. Differences between treatment and control analysed with unpaired t-test. No 















































































3.2 | The Effects of Acetate on Total Cellular Protein Content 
  
The Bradford Assay was used to determine the total protein content of cells 
treated with acetate for 24 hours (Figure 17).  
In HCT116 cells, 25 mM acetate treatment caused a significant decrease in 
protein content compared to the untreated control (76.66 ± 5.52% of the control, p 
= 0.005). Lower doses of acetate (20 – 1 mM) had no significant effect on protein 
content.  
In MCF7 cells treated with 5 mM acetate, protein content was significantly 
increased relative to the untreated control (117.30 ± 5.43% (p = 0.024). All other 
doses of acetate had no significant effect on protein content.  
In MCF10A cells, acetate treatment had no significant effect on total protein 
content compared to the untreated control at any dose.  






Figure 17 | The Effect of Acetate on Total Protein Content. Bars represent mean ± SEM total 
protein content as a percentage of the untreated control (dashed horizontal line), from n = 5 
individual experiments. Differences between treatment and control analysed with unpaired t-
test. * indicates significance (p <0.05) with respect to the negative control. No asterisk means 
























































































































3.3 | The Effect of Acetate on Apoptosis 
  
To further determine the effect of acetate on cellular health, the Annexin V-
FTIC assay was used to investigate to effect of acetate on apoptosis induction 
compared to an untreated control (Figure 18).  
In each cell line tested, 24-hour treatment with 10 mM acetate had no 





Figure 18 | The Effect of Acetate on Apoptosis. Bivariate dot plots (Representative) show 
cells/events plotted as function of Annexin V intensity (x-axis) and PI intensity (y-axis) MFI. 
Events in bottom right and top right quadrants were considered apoptotic.  Bars represent 
mean percentage of total apoptotic events ± SEM from n = 5 individual experiments. 
Differences between control and acetate treatments analysed with Unpaired Student’s t-test. 































































































3.4 | The Effect of Acetate on Autophagy Induction 
  
The effect of acetate compared to an untreated control on autophagy 
induction was measured via flow cytometry (Figure 19). In HCT116 and MCF7 
cells, 24-hour treatment with 10 or 25 mM acetate had no significant effect on 






Figure 19 | The Effect of Acetate on Autophagy. Bars represented mean autophagy induction 
as a percentage of the untreated control ±SEM of n = 3 individual experiments. Differences 
between treatment and control analysed with unpaired t-test. * indicates significance (p 



















































































3.5 | The Effects of Acetate on Mitochondrial Respiration. 
 
The SeaHorse MitoStress Assay was used to investigate whether acetate 
affected mitochondrial function. When treated with 10 mM acetate for 24 hours, 
HCT116 and MCF7 cell lines showed a general reduction in oxygen consumption 
rate (OCR) compared to the untreated control, whilst in the control cell line 
MCF10A, OCR appeared relatively unaffected (Figures 20 and 21).  
In HCT116, 24-hour treatment with 10 mM acetate significantly decreased 
basal respiration (79.63 ± 1.36% of the control, p = 0.039), maximum respiration 
(79.10 ± 7.08% of the control, p = 0.042) and ATP production (79.71 ± 7.33% of 
the control, p = 0.039) compared to the untreated control. OCR associated with 
proton leak trended towards a decrease compared to the control, but did not reach 
significance. (79.01 ± 8.25% of the control, p = 0.052). Acetate treatment had no 
significant effect on the remaining parameters: spare capacity and non-
mitochondrial respiration. 
In MCF7 cells, treatment with acetate caused a significant decrease in 
maximal respiration (79.34 ± 3.83% of the control, p = 0.002) and spare respiratory 
capacity (69.52 ± 7.96% of the control, p = 0.013) relative to the control. Acetate 
treatment had no significant effect on basal respiration, ATP production, proton 
leak, and non-mitochondrial respiration. 
In MCF10A cells, acetate treatment had no significant effect on any 














Figure 20 | The Effect of Acetate on Mitochondrial Respiration. Bar graphs show the individual 
parameters of the MitoStress test, presented as the mean percentage of the negative control 
±SEM of n = 3 independent experiments in each cell line. Differences between treatment and 
control analysed with unpaired t-test. * indicates significance (p <0.05) with respect to the 



















































































































































































































Figure 21 | The Effect of Acetate on Mitochondrial Respiration: MitoStress OCR Proflies. 
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3.6 | The Effect of Acetate on the Production of ROS. 
 
The effect of 24-hour acetate treatment on the production of ROS was 
measured using the DCFDA Assay via fluorescence spectroscopy (Figure 22). In 
all cell lines, acetate induced an increase in ROS levels.  
 In HCT116 cells, 1-20 mM acetate treatments induced a significant increase 
in ROS, with 10 mM, the priming dose, causing a 137% ± 11.82 p = 0.029 
increase compared to the untreated control. Treatment with 25 mM acetate had no 
significant effect on ROS levels compared to the control (p = 0.119).  
In MCF7 and MCF10A cells, treatment with acetate caused a dose 
dependent increase in ROS production. In MCF7, ROS levels in treatments 10 mM 
(114% ± 4.54 of the control, p = 0.040) and above were significantly higher than 
the untreated control. In MCF10A, ROS levels in all doses of acetate were 
significantly higher than the control, with 10 mM, the dose used in priming 








Figure 22 | The Effect of Acetate on Reactive Oxygen Species. Bars represent mean ±SEM ROS 
levels as a percentage of the untreated control (dashed horizontal line), from n = 5 individual 
experiments. Differences between treatment and control analysed with unpaired T-test. 
Significance compared to the untreated control indicated by * = p < 0.05, ** p <0.01. No 





































































































3.7 | The Effect of Acetate on Intracellular Ca2+ 
  
The effect of 24-hour acetate treatment on intracellular calcium was 
measured using the Fluo-4 Direct assay via fluorescence spectroscopy (Figure 
23). In all cell lines tested, acetate caused a dose-dependent increase in Ca2+ 
compared to the untreated controls, with doses of 5 mM and above causing 
significant increases compared to the untreated control. In 10 mM treatments, the 
dose used in priming experiments, Ca2+ levels were increased to 124.4 ± 2.44% (p 
= 0.002) of the control in HCT116, 117.5 ± 2.51% (p = 0.006) in MCF7 cells, and 





Figure 23 | The Effect of Acetate on Intracellular Calcium. Bars represent mean ±SEM Ca2+ 
levels of each treatment group as percentage of the untreated control (dashed horizontal line), 
from n = 4 individual experiments. Differences between treatment and control analysed with 
unpaired T-test.  Significance compared to the untreated control indicated by * = p < 0.05, ** p 
































































































3.8 | The Effect of Acetate on Mitochondrial Morphology 
 
Mitochondrial imaging of HCT116 and MCF7 cells using MitoTracker Deep 
Red via confocal microscopy demonstrated a clear change in mitochondria 
morphology (Figure 24). In HCT116 cells, the mitochondria were smaller and more 
fragmented in cells treated with 10 mM acetate compared to the untreated control. 
In MCF7 cells treated with acetate, the mitochondria appeared less numerous but 
larger and more intense, which may suggest swelling. In MCF10A, there was no 
discernible difference between the negative control and 10 mM acetate-treated 
cells.  
The MitoLOC plugin for ImageJ/FIJI was used to quantify changes in the 
mitochondrial morphology from the obtained images (Figures 25, 26 and 27). 
 In HCT116 cells, treatment with 10 mM acetate caused a significant 
decrease in the average number of mitochondria per cell (17.73 ± 1.34 vs 21.78 ± 
1.34, p = 0.017). There was no significant change in average surface area of 
mitochondria per cell and in the average total mitochondrial area in cells treated 
with acetate compared to untreated cells.  
In MCF7 cells, the average number of mitochondria per cell was also 
significantly lower in acetate treated cells (20.84 ± 1.381 vs 26.82 ± 1.925, p = 
0.013). The average area of mitochondria and the average total mitochondria in 
acetate-treated cells were not significantly different compared to untreated cells. 
In MCF10A cells, the average number of mitochondria per cell trended 
towards an increase in acetate treated cells but did not reach statistical 
significance (43.81 ± 2.457 vs 35.74 ± 3.658, p = 0.0674). The average of area of 
individual mitochondria was significantly decreased by acetate treatment (2138 ± 
157.6 vs 2806 ± 250.5, p = 0.0305), whilst the average total mitochondrial area per 
cell was not significantly different compared to untreated cells.   
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Figure 25 |The Effect of acetate on HCT116 Mitochondrial Morphology – MitoLOC. Images 
were quantified by the analysis of MitoTracker Deep Red stained cells by the ImageJ plugin, 
MitoLOC. Cells were treated with media (grey) or 10 mM acetate (orange) for 24 hours. 
Individual points indicate the number of mitochondria per cell, average mitochondrial area per 
cell, and total mitochondrial area per cell. 5 cells were analysed per image. 3 images were 
captured for each condition, in n = 5 individual experiments, to give a total of 75 analysed. 
Differences between treated and control analysed with Unpaired Student’s T-test. * indicates 












































































Figure 26 | The Effect of acetate on MCF7 Mitochondrial Morphology – MitoLOC. Images 
were quantified by the analysis of MitoTracker Deep Red stained cells by the ImageJ plugin, 
MitoLOC. Cells were treated with media (grey) or 10 mM acetate (orange) for 24 hours. 
Individual points indicate the number of mitochondria per cell, average mitochondrial area per 
cell, and total mitochondrial area per cell. 5 cells were analysed per image. 3 images were 
captured for each condition, in n = 5 individual experiments, to give a total of 75 analysed. 
Differences between treated and control analysed with Unpaired Student’s T-test. * indicates 












































































Figure 27 | The Effect of acetate on MCF10A Mitochondrial Morphology – MitoLOC. Images 
were quantified by the analysis of MitoTracker Deep Red stained cells by the ImageJ plugin, 
MitoLOC. Cells were treated with media (grey) or 10 mM acetate (orange) for 24 hours. 
Individual points indicate the number of mitochondria per cell, average mitochondrial area per 
cell, and total mitochondrial area per cell. 5 cells were analysed per image. 3 images were 
captured for each condition, in n = 5 individual experiments, to give a total of 75 analysed. 
Differences between treated and control analysed with Unpaired Student’s T-test. * indicates 









































































Flow Cytometry was used as an additional method to quantify the observed 
changes in morphology (Figure 28). In each cell line, the higher 25 mM acetate 
dose induced an increase in fluorescence intensity compared to the untreated 
control. 
 In HCT116 cells, 10 mM acetate treatment had no significant effect on 
MitoTracker intensity. 25 mM treatment significantly increased intensity to 139.7 ± 
16.75% of the control (p = 0.0178). 
In MCF7 cells, 10 mM acetate had no significant effect on MitoTracker 
intensity. 25 mM treatment significantly increased intensity to 125.0 ± 7.307 % of 
the control (p = 0.026). 
In MCF10A cells, 10 mM acetate had no significant effect on MitoTracker 
intensity. 25 mM treatment significantly increased intensity to 117.6 ± 3.123 % of 





Figure 28 |The Effect of Acetate on Mitochondrial Morphology – Flow Cytometry. 
Morphology was quantified by changes in MitoTracker Deep Red Intensity. HCT116, MCF7, and 
MCF10A cells were treated with media or acetate for 24 hours. Data presented as mean 
changes in signal intensity of n = 4-7 individual experiments, compared to an untreated control 
±SEM. Differences between treated and control analysed with Unpaired Student’s T-test. * 
indicates significant (p <0.05) difference between means.  No asterisk means not statistically 


































































































































3.9 | The Effect of Acetate on Gene Expression 
  
The effect of 24-hour 10 mM acetate treatment on the expression of 
ACSS1, ACSS2, VDAC1, P53, and NRF2 was measured using qPCR (Figure 29).  
In acetate-treated HCT116 cells, the expression of P53 and NRF2 was 
significantly decreased compared to the untreated control (0.64 ± 0.04 fold 
decrease p = 0.014 and 0.81 ± 0.003 fold decrease p = 0.0004 respectively). The 
expression of ACSS2 and VDAC1 were unaffected by acetate treatment. ACSS1 
was not expressed in HCT116 cells. 
In MCF7 cells, acetate treatment significantly increased the expression of 
ACSS2 compared to untreated cells (1.15 ± 0.02 fold increase p = 0.002). The 
expression of VDAC1, P53, ACSS1 and NRF2 in acetate-treated cells were not 
significantly different compared to the control. 
 In MCF10A cells, acetate treatment significantly increased the expression 
of ACSS2 and VDAC1 (1.27 ± 0.04 (p = 0.021) and 1.18 ± 0.03 (p = 0.032) fold 
increases respectively). The expression of ACSS1, P53 and NRF2 were 








Figure 29 | The Effect of Acetate on Gene Expression. Bars represent mean fold change in 
mRNA expression compared to the untreated control (dashed horizontal line), from n = 3-4 
individual experiments. Differences between treatment and control analysed with unpaired T-
test.  Significance compared to the untreated control indicated by * = p < 0.05, *** p < 0.001. 




































































































































3.10 | The Effect of Acetate on the Cell Cycle 
 
 The effect of 24-hour acetate treatment on cell cycle state was measured 
using PI flow cytometry (Figure 30).  
In this experiment, only HCT116 cells were tested due to difficulties with the 
other cell lines forming aggregates and causing blockages in the flow cytometer 
(discussed in more detail in Section 3.14.7). In HCT116 cells, 25 mM acetate 
treatment induced a significant decrease in the number of cells in the G0-G1 phase 
compared to the untreated control (mean decrease of 11.89 ± 4.88% p = 0.029). 
There was no significant change in S phase population between any treatment 
groups. 10 mM and 25 mM acetate treatments induced a significant dose 
dependent increase in cells in the G2-M phase (mean increases of 6.31 ± 2.69% p 
































Untreated 10 mM Acetate 25 mM Acetate 
Figure 30 | The Effect of Acetate on the Cell Cycle. Bar charts (top) show the mean 
populations (as a percent of total cell count) ±SEM in the 3 major cell cycle phases: G0-G1, S 
and G2-M. Differences between treatment group and untreated control analysed with 
student’s t test. Significance compared to the untreated control indicated by * = p < 0.05, ** = 
p <0.01. n = 8. Histograms below represent typical univariate histogram plot intensity of PI 




































3.11 | The Effect of Acute Acetate Treatment on Mitochondrial Function  
 
 The short-term effects of acetate on mitochondrial function were measured 
using the SeaHorse XFe24 analyser (Figure 31). In each cell line, injection of 
acetate to a final concentration of 10 mM induced an immediate increase in OCR 
which continued to increase over the course of the assay.  
After 12 hours, OCR in HCT116 cells was significantly increased to 129.6 ± 
5.90% of the control (p = 0.0074). In MCF7 and MCF10A, acetate injection had no 
significant effect on OCR recorded after 12 hours.   
 Correspondingly, the injection of acetate into each cell type caused an 
immediate decrease in ECAR, which was sustained over the course of the assay. 
After 12 hours, ECAR was significantly reduced in each cell line: 81.31 ± 2.14% of 
the control in HCT116 (p = 0.0009), 82.60 ± 2.19% of the control in MCF7 (p = 







Figure 31 | The Effect of Acute Acetate Treatment on Mitochondrial Respiration.  Lines 
represent mean OCR (left) or ECAR (right) change compared to the untreated control (dashed 
horizontal line) before and after the injection of acetate (dashed vertical line), from n = 5 
individual experiments. Differences between treatment and control at the end of the assay 
analysed with unpaired T-test.  Significance compared to the untreated control indicated by * = 















































































































































3.12 | The Effect of Acute Acetate Treatment on Glycolysis 
 
 The short-term effects of acetate on glycolysis were measured with the 
SeaHorse GlycoStress Assay using the SeaHorse XFe24 Analyser (Figures 32 
and 33). 
  In HCT116 cells, acetate injection caused a significant decrease in 
glycolysis (77.28 ± 4.05% of the control p = 0.003), glycolytic capacity (77.26 ± 
4.38% of the control p = 0.003), and non-glycolytic acidification (92.86 ± 2.20% of 
the control p = 0.023). Glycolytic reserve trended towards a decrease in acetate 
treated cells, but this change was not statistically significant (73.32 ± 11.07% of 
the control p = 0.061). 
 Acetate treatment also caused a significant decrease in glycolysis in MCF7 
cells (68.76 ± 5.56% of the control p = 0.003). Glycolytic capacity and non-
glycolytic acidification remained unchanged following acetate injection. Glycolytic 
Reserve was significantly increased by acetate treatment (125.60 ± 9.33% of the 
control p = 0.041). 
 Acetate treatment had no significant effect on any of the measured 




Figure 32 | The Effect of Acute Acetate Treatment on Glycolysis. Bar graphs show the 
individual parameters of the GlycoStress test, presented as the mean percentage of the 
negative control ±SEM from n= 6 independent experiments.  Significance compared to the 
untreated control indicated by * = p < 0.05, ** = p < 0.01, *** p < 0.001. No asterisk means not 



































































































































































Figure 33 | The Effect of Acute Acetate Treatment on Glycolysis – GlycoStress ECAR Profiles. 
Lines show change in ECAR over course of the Assay following the injection of media (grey) or 
acetate (orange), as indicated the by dashed vertical line. 
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3.13 | The Effect of Acute Acetate Treatment on Intracellular Ca2+ 
 
 The short term effects of acetate on intracellular Ca2+ ([Ca2+]i) were 
monitored by observing the changes in Fluo4 Direct fluorescence prior to and 
following the injection of acetate using the BMG NOVOStar fluorescence plate 
reader (Figure 34).  
In HCT116 cells, injection of acetate caused an immediate increase in 
[Ca2+]i, reaching a peak at 32.06 seconds of 113.90 ± 4.42% of the control that 
was significantly higher than the control (p = 0.027). [Ca2+]i levels then dropped to 
108.60 ± 3.88% of the control by the end of the measurement period, which was 
not significantly higher than the control. 
 In MCF7 cells, injection of acetate did not cause an immediate increase in 
[Ca2+]i, but rather caused a smaller, yet sustained increase over the course of the 
measurement period. At the end of the assay, [Ca2+]i had increased to 102.2 ± 
1.30% of the control, which was significantly higher than the control (p = 0.019). 
 In MCF10A cells, injection of acetate caused a trend towards an immediate 
increase in [Ca2+]i, reaching a peak at 26.22 seconds of 108.20 ± 3.52% of the 
control, yet was not statistically significant (p = 0.067). [Ca2+]i levels then dropped 
to 104.00 ± 1.84% of the control by the end of the measurement period, which was 






Figure 34 | The Effect of Acute Acetate Treatment on Intracellular Calcium. Orange data 
points mean represent [Ca2+]i fluorescence as a percentage of PBS treated cells (dashed 
horizontal line) ± SEM of n = 5-6 individual experiments. Dashed vertical line indicates the time 
point at which acetate or PBS was injected into well. Differences in fluorescence between 
treatment and control at the peak and at the end of the assay were analysed with unpaired T-
test.  Significance compared to the untreated control indicated by * = p < 0.05. No asterisk 














































































































3.14 | Discussion 
 
3.14.1 | The Effects of Acetate on Cell Viability and Apoptosis 
 
 In the first part of this study I assesed what effect that a range of acetate 
doses had on cell viability. The objective was two-fold: to answer whether acetate 
alone could affect cell viabilty or induce apoptosis, and to determine if this affect 
was limited to cancer cells.  
Data gathered from the MTT viability assay suggests that 1-25 mM acetate 
treatment had no significant effect on the viability of both the cancerous and non-
cancerous cell lines after 24 hours. 
The results of an MTT assay can be considered ambiguous; as the 
conversion of MTT to formazan is catalysed by NADPH oxireductases (Berridge 
and Tan, 1993), changes in observed cell viabilty could correspond to changes in 
metabolic activity, cellular proflieration, or cell death, any of which can lead to a 
decrease in total enzymatic activity and result in changes in formazan production 
(Riss TL, Moravec RA, Niles AL, 2013; Wang et al., 2010). I therefore used 
another test, the Bradford assay, to quantify the total protein content in a 
population of cells following treatment with acetate and confirm the observations 
from the MTT assay. Results from the Bradford assay showed that each 
concentration of acetate tested had no significant effects on cell population in 
terms of protein content, corroborating the MTT results with one exception: 
HCT116 cells treated with 25 mM acetate, in which there was a significant 
decrease in protein content. In the MTT assay, HCT116 viabilty appeared to be 
reduced following 25 mM acetate treatment, but the difference was not signifcant 
compared to the untreated control. It may be possible that 25 mM acetate is 
sufficicent to induce cell death alone, but further work is needed to confirm this.  
Finally, results of the Annexin V apoptosis assay confirmed that 10 mM 
acetate treatment does not induce significantly more apoptosis compared with the 
untreated control in any cell line. The combination of results from each assay 
provides strong evidence that the concentrations of acetate used in this study are 
not sufficient to kill cells alone, a finding that aligns with literature which reports 
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that lower concentrations of acetate (1-20 mM) have little to no effect on 
proliferation or apoptosis  (Comalada et al., 2006). Marques et al. found that 
higher concentrations (70-220 mM) caused significant decreases in viability in 
HCT-15 and RKO colorectal cancer cell lines, which may support the observation 
in this study that 25 mM treatment decreased total protein content in HCT116 cells 
(Marques et al., 2013).  
The effect of acetate on cell viability and apoptosis is shown in this study to 
be muted compared to literature investigating propionate and butyrate. Butyrate in 
particular is consistently shown to have the strongest effect on viability and 
apoptosis, for example being shown to induce apoptosis in HT29 colorectal cancer 
cells at concentrations of 5 mM (Wang et al., 2009). In an earlier study, Hague et 
al. found that a 4 day treatment with 4 mM butyrate caused significant decreases 
in cell number in a range of adenoma and carcinoma cell lines, as did treatment 
with 4-10 mM propionate, whilst effects from acetate treatment were only seen at 
concentrations of 40 – 80 mM (Hague et al., 1995). Furthermore, Hinnebush et al. 
found that growth inhibition of HT29 and HCT116 colorectal cancer cells was 
highest following butyrate treatment, followed by propionate and then acetate. 
Whilst this and other studies may seem to indicate that the effect size on apoptosis 
or viability increases with increasing SCFA length, the group went on to show that 
the effect is reduced with SCFAs longer than butyrate, with caproate (C6) having 
an effect on cells similar in magnitude to acetate. Why butyrate has the strongest 
effect has yet to be explained; Hinnebusch, attributing the apoptotic effect of the 
SCFA to histone acetylation, speculated that butyrate may have a greater affinity 
for certain HDAC isozymes, but conceded that further work is needed to further 
elucidate this mechanism  (Hinnebusch et al., 2002).  
By comparison, the effects of the SCFA on viability the of cell types other 
than colorectal are not as widely investigated in existing literature, which may be 
because the colon is the site of SCFA production and thus where they are found in 
highest concentrations. Yonezawa et al. detected the expression of SCFA 
receptors in MCF7 and subsequently found that the SCFAs, including acetate, 
increased cellular Ca2+ and phosphorylated proteins including heat shock protein 
27 and p38. However, the group did not investigate any effect on cellular health 
(Yonezawa et al., 2007).   
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3.14.2 | The Effects of Acetate on Mitochondrial Respiration 
 
The SeaHorse MitoStress assay provides a high-throughput means of 
quantifying the consumption of oxygen as a measure of mitochondrial function. 
Decreases in mitochondrial function could suggest potential modulation of 
mitochondrial function, switches in metabolic phenotyping, or general 
mitochondrial stress (Dranka et al., 2011). Inhibition of OXPHOS has been 
investigated as an apoptosis-inducing mechanism in anti-cancer drugs, such as 
staurosporine and taurol, which have been shown to trigger apoptosis in an 
OXPHOS-dependent manner, inducing mitogenesis and an accompanying 
increase in ROS production (Yadav et al., 2015). Additionally, “reversing the 
Warburg effect”, by increasing oxygen consumption, has also been shown to 
inhibit glioblastoma growth both in vitro and in vivo (Poteet et al., 2013). 
Decreased OXPHOS as a result of mitochondrial damage or remodelling would 
also be consistent with mitochondrial changes observed in the intrinsic pathway of 
apoptosis (Cosentino and García-sáez, 2014). Targeting OXPHOS in this manner 
has been demonstrated to be effective in other drugs or molecules, such as 
epigallocatechin-3-gallate (ECCG), which was shown to target complexes I, II and 
ATP Synthase within the ETC (Valenti et al., 2013) and Elesclomol, which 
supresses OXPHOS via down-regulation or suppression of a number of proteins, 
including Complex I (Barbi de Moura et al., 2012).   
In the cancerous cell lines HCT116 and MCF7, treatment with acetate 
caused a general decrease in mitochondrial function. This effect was strongest in 
HCT116, in which basal, maximal and ATP production-associated oxygen 
consumption rates were significantly decreased, whereas MCF7 by comparison 
experienced decreased maximal respiration rates only. Additionally, acetate 
treatment of MCF7 cells caused a significant decrease in spare respiratory 
capacity, which, as measure of the ability of the mitochondria to respond the 
increased energy demand (Brand and Nicholls, 2011), may indicate mitochondrial 
dysfunction, as the capacity to respond to stress is diminished. Interestingly, 
proton leak – the dissipation of the proton gradient across the inner mitochondrial 
membrane that is not attributable to ATP production, trended towards a decrease 
in both cancer cell lines. Proton leak can be categorised into basal, which is cell 
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type specific, and inducible, regulated by proteins such as the adenine nucleotide 
translocator (ANT) and the uncoupling proteins (UCPs). Inducible proton leak has 
an important role in brown adipose tissue in heat production (Jastroch et al., 
2010), but can also be an indication of mitochondrial damage. Considering the 
observed decrease in other mitochondrial function parameters tested, one might 
expect to have seen an increase in proton leak following acetate treatment. This 
result, whilst it did not reach statistical significance (p = 0.052 in HCT116 and p = 
0.069 in MCF7) warrants further investigation – which could include measuring 
mitochondrial membrane potential.  An interesting consideration is that inducible 
proton leak has a role in removing ROS, so an inhibition in the mitochondria’s 
ability to expel ROS could contribute to oxidative stress (Roland et al., 2011). 
Alternatively, the decrease in proton leak may simply arise as a result of the 
overall decrease in OCR relative to the untreated control. The final MitoStress 
parameter, non-mitochondrial respiration, is unaffected in both cancer cell lines, 
which confirms that changes in OCR are a direct result of changes to the 
mitochondria, and not mediated through changes in other oxygen-consuming 
processes in the cell, such as NADPH oxidase activity (Brand and Nicholls, 2011). 
Interestingly, acetate treatment did not appear to have any effect on the 
mitochondrial function of the non-cancerous MCF10A cells, which at this stage 
could suggest that acetate has no effect on MCF10A cells, or that any effect may 
not be sufficient to modulate mitochondrial function.  
 
3.14.3 | The Effects of Acetate on ROS  
 
The decreased mitochondrial function could be an indication that acetate 
induces oxidative stress in cancer cells. To investigate this further, I measured a 
key marker of mitochondrial stress: ROS.  
The production of ROS is a well-established indicator of cellular stress 
(Cadenas and Davies, 2000). Primarily produced from the mitochondria as a by-
product of oxidative phosphorylation, increasing ROS levels has been identified as 
the mechanism in a number chemosensitisation studies using natural products, 
such as the sensitization of cells to DDP-induced cell death by saikosaponins, 
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curcubitacin B (El-Senduny et al., 2015) and Boswellia ovalifoliolata (Thummuri et 
al., 2014). Thus, the intentional induction of ROS is being increasingly  identified 
as a new approach in cancer therapy (Zou et al., 2017).  
ROS levels in acetate-treated cell lines were analysed via the DCFDA 
microplate assay. I found that ROS levels were increased following 24 hour 
treatment with 1-25 mM acetate in all cell lines. In MCF7 and MCF10A, this effect 
followed a strong dose-dependent pattern. In the cancer cell lines, the increased 
levels of ROS could provide an explanation for the observed decrease in 
mitochondrial function: being in close proximity to the site of ROS production, 
mtDNA is particularly sensitive to ROS-induced damage and therefore can result 
in decreased mitochondrial function (Shokolenko et al., 2009). Furthermore, ROS 
is known to inactivate and degrade mitochondrial proteins such as NADH 
dehydrogenase and NADH oxidase, again leading to inhibited function (Cadenas 
and Davies, 2000). ROS levels were also increased in the non-cancerous 
MCF10A cells in which acetate, based on SeaHorse results described in Section 
3.14.2, had no impact on mitochondrial function. An explanation for this may be 
rooted in intrinsic differences in cancer cell metabolism: basal ROS levels are 
elevated in cancer cells to drive signalling pathways associated with promoting 
cellular proliferation (See Section 1.3.5). Thus ROS acts as double-edge sword to 
cancer cells, as it also renders them sensitive to further augmentations in ROS 
levels (Schumacker, 2006). Therefore, whilst acetate may be inducing stress in 
MCF10A cells, it would not appear to be sufficient to damage the mitochondria and 
induce a state of oxidative stress.  
The DCFDA assay is one of the most widely used probes to measure ROS 
(Eruslanov and Kusmartsev, 2010), yet there are several caveats to its use that 
should be considered: chief among these is the complex intracellular chemistry of 
DCDFA, which means it can be oxidised by non-ROS species such as cytochrome 
c (Kalyanaraman et al., 2012). Therefore, to strengthen and expand these 
experiments, future work could include the use of MitoSOX, a mitochondria-
specific probe for the superoxide anion. Not only does this probe provide a direct 
measurement of ROS (Robinson et al., 2008), targeting the mitochondria can also 
strengthen arguments that acetate is inducing mitochondrial stress.  
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3.14.4 The Effects of Acetate on Intracellular Ca2+  
 
 Interactions between the mitochondria and intracellular Ca2+ ([Ca2+]i) can 
provide a mechanistic link between changes in mitochondrial metabolism, 
increases in ROS production, and potentially, sensitivity to apoptosis initiation. 
Because of the relationship between ROS, and Ca2+ (described in section 1.3.7), I 
expected to see an increase in [Ca2+]i to accompany the increased levels in ROS, 
which would further demonstrate that acetate induces oxidative stress. In this 
study, I found that 24 hour 10 mM acetate treatment increased levels of [Ca2+]i in a 
dose-dependent manner. 
It is important, however, to consider here the nature of the increased [Ca2+]i 
signal in this study, and how changes in signal can be interpreted. The Fluo-4 
stain used in this study is not targetable to specific organelles; the esterases that 
hydrolyse the dye are primarily (but not exclusively) localized in the cytoplasm, 
meaning an increase in Fluo-4 signal could correspond to increased [Ca2+] 
anywhere in the cell (Contreras et al., 2010). Total cellular Ca2+ can be considered 
to have two sources: entry from the outside the cell or release from internal stores, 
such as the ER or mitochondria (Contreras et al., 2010). Therefore, at this stage I 
cannot exclude the possibility that an increase in signal could be a consequence of 
Ca2+ entry from either source. However, in a review of commonly used Ca2+ stains, 
Thomas et al. found that following immediately following loading, Fluo-4 initially 
displays a uniform cytoplasmic signal, accompanied by a more intense, yet 
uniform signal in the nucleus. Interestingly, after a 30 minute incubation at 37ºC, 
images revealed a marked mitochondrial/ER accumulation (Figure 35) (Thomas et 
al., 2000). As this 30 minute, 37ºC incubation was used in the protocols in this 
study, the observed increased [Ca2+] signal following acetate treatment may 




The sustained increased of Ca2+ in the mitochondria ([Ca2+]m), known as 
calcium overload, is known to cause oxidative stress and is considered an 
important contributor to mitochondrial ROS production, generating ROS through a 
number of mechanisms. Such pathways include the indirect stimulation of 
OXPHOS through TCA cycle activation, resulting in a boost in OXPHOS substrate 
synthesis (e.g. NADH and FADH) (Feissner et al., 2009), nitric oxide production 
(Peng and Jou, 2010), and Ca2+-mediated opening of the mitochondrial 
permeability transition pore (mPTP). In the latter mechanism, cytochrome c 
escape through the mPTP is thought to inhibit electron transfer between complex 
III and IV in the ETC (See Section 1.3.4, Figure 3 and Table 1), with the 
subsequent ETC dysfunction resulting in increased ROS production (Peng and 
Jou, 2010). Although Ca2+ is widely known to be essential to the process, the 
mechanism by which [Ca2+]m triggers mPTP opening remains poorly understood, in 
part due to the yet-unresolved composition of the mPTP (Wong et al., 2012).  
Although now not generally considered an essential component of the 
mPTP (Kwong and Molkentin, 2015), voltage-dependent anion channels (VDACs), 
are important regulators of [Ca2+]m and may also play a role in acetate-induced 
changes in [Ca2+]m. Interactions with VDAC have been identified as the 
mechanisms by which CBD causes changes in [Ca2+]m; inhibition of VDAC1 by the 
A B 
Figure 35 | Mitochondrial Accumulation of the Fluo-4 Calcium Dye. Loading HeLa cells with 1 
µM Fluo-4 initially shows a uniform distribution in the cytosol, with a more intense, yet 
uniform distribution in the nucleus  (A). After 30 minutes incubation at 37°C, Fluo-4 shows 
marked mitochondrial/ER accumulation (B) Images taken from Thomas et al., 2000. 
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cannabinoid CBD has been shown to induce apoptosis in BV-2 murine microglial 
cells (Rimmerman et al., 2013), and prime breast cancer cell lines for DDP-
induced cell death via decreased expression of the VDAC1 gene (Henley, 2015). 
The effect of acetate on VDAC expression will be discussed in more detail in 
Section 3.14.8.  
Another molecule implicated in the mPTP is the adenine nucleotide 
translocator (ANT), the presence of which is more conserved in proposed models 
of the mPTP compared to VDAC (Kwong and Molkentin, 2015). ANT sits on the 
IMM and exchanges OXPHOS-produced ATP for ADP. Because of its role in 
supplying the ETC with ADP, ANT activity is essential for maintaining OXPHOS 
activity. ANT is also thought to act as a mitochondrial uncoupler – mediating 
proton leak across the mitochondria membrane and decreasing mitochondria 
membrane potential (Δψm). As ROS production increases with Δψm, ANT and 
other uncoupling proteins are thought to play a role in protecting the mitochondria 
against oxidative damage (Kim et al., 2010). ANT (specifically the ANT2 isoform)  
may have a role in supporting cancer cell metabolism, as it has been found when 
OXPHOS activity is impaired, ANT can supply the mitochondria with glycolytically-
produced ATP into the mitochondria, maintaining mitochondrial integrity and 
thereby promoting cellular survival (Chevrollier et al., 2011). Targeting ANT may 
therefore may present an important target in promoting cancer cell death or 
increasing sensitivity to apoptotic treatments. Interestingly, work by Jan et al. 
suggested ANT has a role in how the SCFAs induce apoptosis, as inhibition of 
ANT removed the apoptotic effect of mixed acetate/propionate treatment in HT29, 
HeLa, and Caco2 cancer cell lines (Jan et al., 2002). In addition, valproic acid 
(VPA, a branched SCFA that like acetate, propionate, and butyrate has HDAC 
inhibitory activity), regulated expression of ANT (specifically, ANT4), which the 
authors speculate may contribute to the observed VPA-induced [Ca2+]m. overload 
(Ji et al., 2015). Thus, it may be useful to observe how acetate affects ANT 
expression, particularly in light of my data showing acetate to have a significant 
effect on mitochondrial metabolism.  
Mitochondrial calcium overload is also known to affect changes in 
mitochondrial morphology, such as swelling or fragmentation of the mitochondrial 
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network, both of which are early steps in apoptosis initiation (Giorgi et al., 2012), 
which is examined in Section 3.8 and discussed in Section 3.14.5.   
The role of Ca2+ in apoptosis and oxidative stress makes it an attractive 
target in cancer therapy; changes in Ca2+ following treatment are well documented 
in many chemosensitisation and chemopreventative studies, such as in melatonin 
(Dai et al., 2002), resveratrol (Sareen et al., 2007) and curcumin (Xu et al., 2015a). 
Based on the above discussion, it may be possible that the state of oxidative 
stress, characterised by increased ROS and decreased mitochondrial function, 
may be a result acetate-induced calcium overload.  
To confirm this, the short-term effects of acetate on Ca2+ should be 
investigated. Butyrate, the longest of the SCFA, has been found to increase [Ca2+]i 
immediately following treatment, which the authors attributed to interactions with 
the g-coupled protein receptors FFAR2 and FFAR3 (Miletta et al., 2014). Since 
acetate is also known to interact with FFAR2 and FFAR3, (Schug et al., 2016), I 
would propose that through similar interactions, the elevated ROS shown in this 
study is a result of acetate-induced [Ca2+]i increase. This is tested in Section 
3.14.8. 
Crucial to the hypothesis that oxidative stress is induced by acetate 
mediated mitochondrial Ca2+ overload is that the observed increased in Ca2+ 
fluorescence is caused by increased mitochondrial Ca2+. Therefore, despite 
Thomas et al. demonstrating Fluo-4 may accumulate in the mitochondria and/or 
ER, it is essential that  future work should include the use of mitochondrial-specific 
Ca2+ probes, such as Rhod2 (ThermoFisher, UK) (Fonteriz et al., 2010).   
 
3.14.5 | The Effects of Acetate on Mitochondrial Morphology 
 
To further understand the observed changes in mitochondrial function 
described in Section 3.14.2, the mitochondria of 24 hour 10 mM acetate or media-
treated cells were observed using the MitoTracker DeepRed stain via confocal 
microscopy (figure 20). From visual observations, the mitochondria of cells treated 
with 10 mM acetate for 24 hours seemed to reduce in length (more apparent in 
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HCT116 cells) or swell (more apparent in MCF7 cells) compared to their untreated 
counterparts. SCFA-induced swelling has been observed following acetate and 
propionate treatment of isolated mitochondria, which implied that bacterially-
produced SCFA induced-apoptosis was mediated by the mitochondria (Jan et al., 
2002). The morphology of MCF10A mitochondria, despite the cell line following 
similar dose-dependent increases in ROS and Ca2+ as the cancer cell lines, 
appeared unaffected by acetate treatment. 
In order to quantify these subjective changes, images were analysed using 
the MitoLOC plugin for ImageJ. My analysis found that the number of mitochondria 
per cell was significantly decreased in both HCT116 and MCF7 cells compared to 
untreated cells. However, there were no changes in the average area of individual 
mitochondria or the average total mitochondrial area per cell. In contrast, acetate 
treatment of MCF10A cells caused a significant decrease in average mitochondria 
area, whilst having no significant effect on the number of mitochondria per cell. In 








Fusion Decreased Increased No change 
Fission Increased Decreased No change 




The data from HCT116 and MCF7 cells would therefore suggest that 
acetate is not inducing fusion, fission or mitophagy. Fewer mitochondria per cell is 
however consistent with the decreased function observed in Section 3.14.2. 
Acetate may induce fission in MCF10A cells, as there is a trend towards increased 
mitochondrial number per cell following acetate treatment (p = 0.06).  
Fission of mitochondria is a pre-requisite step in apoptosis, and is also 
associated with oxidative stress (Frank et al., 2012) (As described in Section 
Table 11 | Interpretation of MitoLOC Data. The three parameters measured in the MitoLOC 
image analysis, and what changes in each could mean in terms of mitochondrial dynamics.   
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1.3.1). This observation is therefore contrary to results from this study which 
indicate that acetate treatment is not sufficient to induce oxidative stress in 
MCF10A cells. One plausible explanation could be that the apparent acetate-
induced fission in MCF10A is a pre-requisite step for the removal of damaged 
mitophagy, preparing to clear damaged mitochondria in order to mitigate a state of 
oxidative stress. This response has been observed following ROS accumulation 
(Frank et al., 2012), which is also observed in MCF10A cells in this study following 
ROS treatment.  
Overall, whilst acetate does induce significant effects in mitochondrial size 
and number it is unclear exactly what these changes mean in terms of fission, 
fusion and mitophagy. It is therefore crucial for future work to include 
investigations into the detection of mitophagy, for which several techniques are 
available, including flow cytometry of MitoTracker-labelled cells in combination 
with mitophagic and lysosomal inhibitors (Mauro-lizcano et al., 2015), using 
fluorescence microscopy to monitor localization of mitochondrial markers to 
autophagic machinery markers (Dolman et al., 2013) or western blot for 
mitochondrial proteins (Ding and Yin, 2012), which were unfortunately not possible 
in this study due to financial constraints.  
 Additionally, mitochondria are highly dynamic structures, and can move at 
along cytoskeleton networks at speeds of up to 5 µm per second (Zheng et al., 
2010), and fusion and fission events have been shown to occur at a rate of 
approximately 1 event per minute per cell in Dictyostelium discoideum (Woods et 
al., 2016). Therefore, with mitochondria in constant state of flux, single images 
may not represent the full extent of the effect of acetate on mitochondria 
dynamics. Future work should include time lapse images to assess changes in 
dynamics and morphology. This was not possible in current study, as the 
microscope used did not have an incubated stage and had to operate at a 
relatively high power to obtain images, which may photo bleach the stain or affect 
the cells. 
Another point to consider is the impact of acetate-induced increase in Ca2+ 
on mitochondrial morphology. Increased [Ca2+]m overload is associated in 
particular with increased fission (Kaddour-Djebbar et al., 2010). Based on the 
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increased levels of Ca2+ following acetate treatment, one might therefore expect to 
see mitochondrial fission in all three cell lines. However, Ca2+ overload-induced 
fission is also associated with apoptosis (Kaddour-Djebbar et al., 2010), which was 
not observed following acetate treatment in this study. Therefore, the increase in 
Ca2+ caused by acetate treatment may not be of a sufficient level to induce 
apoptotic-associated mitochondrial fission.   
It should be noted that the analysis of the mitochondrial images has several 
weaknesses. Firstly, the MitoLoc plugin was developed for super-resolution 
images; Vowinckel et al. used a 100X objective, whereas due to the setup of the 
Leica SP2, 63X was the highest magnification available to me at the University of 
Westminster for live cell imaging. Secondly, MitoLOC was developed using 
Saccharomyces cerevisiae, which contain fewer mitochondria than human cells, 
making isolation of individual mitochondria far easier. The combination of these 
factors is most apparent when analysing MCF10A cells, which contain large 
numbers of highly interwoven mitochondrial networks, which the MitoLoc plugin 
often counted to be a single, enormous mitochondrion. Nevertheless, the data 
provided is still useful for detecting and quantifying large-scale changes in 
mitochondrial morphology, as long as care is taken to account for these limitations.  
In order to overcome some of these shortcomings, flow cytometry was also 
with the goal of quantifying the intensity of MitoTracker Deep Red in untreated and 
acetate-treated cells, based on work by Tailor et al. Tailor suggested that a 
decrease in MitoTracker Deep Red signal was an indicator of increased 
mitochondrial fusion, and found that treatment with butyrate, the longest of the 
SCFA, resulted in a dose-dependent decrease in what was described as “Active 
Mitochondrial Mass” – and thus increased mitochondrial fusion (Tailor et al., 
2014). The results obtained for HCT116 and MCF7 cells indicated that there was 
no change in signal intensity following treatment with 10 mM acetate, but do show 
significant increases following 25 mM acetate treatment. This is somewhat 
contradictory to the image analysis, as one might expect a decrease in intensity if 
there are fewer mitochondria than in the control.  
This result may be explained by the fact that uptake of the MitoTracker 
Deep Red stain is mitochondrial potential-dependent, and so factors affecting 
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mitochondrial membrane potential could affect the staining intensity (Xiao et al., 
2016). Therefore mitochondria sufficiently damaged by oxidative stress may not be 
visible.  
Overall, the combination of image analysis and flow cytometry data would 
suggest that acetate has a limited effect on mitochondrial shape. However, the 
significant decrease in mitochondrial number per cell in cancer cells, combined 
with decreased function and elevated ROS and Ca2+, could indicate mitochondria 
are being damaged, and subsequently removed by autophagy.  
 
3.14.6 | The Effects of Acetate on Autophagy 
 
 Autophagy is the process by which cells maintain homeostatsis through the 
controlled degradation and recycling of cells or celluar components. Levels of 
autophagy are generally thought to increase under condititions of stress to ensure 
cellular survival. Autophagy and apotosis are interwined – excessive autophagy 
can result in apoptosis, but autophagy has also been considered a response to 
limit apoptosis. This relationship is further complicated in cancer: genes promoting 
autophagy are often found to be under expressed in cancer, yet it is considered an 
essential process to support proliferation and survival in the stressful condtions of 
the tumour microenvironment (Mathew et al., 2007). Based on this, one may 
expect acetate to increase autophagic actvity as a response to the observed 
acetate-induced oxidative stress. This has been reported with propionate and 
butyrate treatments (Tang et al., 2010). Additionally, the significant decrease in 
mitochondrial number observed in response to acetate treatment may be a result 
of mitochondrial degradation, known as mitophagy. However, in this study acetate 
was observed to have no signficant effect on autophagy induction in any cell line. 
Although this may not align with effects of other SCFAs, a lack of autophagy may 
improve the potential of acetate as a priming agent, as autophagy is known to 
mediate and protect against apoptosis (Yonekawa and Thorburn, 2013). 
Furthermore, because of its role in cancer as an alternative fuel, acetate may 
alleviate the conditions of nutrient starvation needed to trigger autophagy. Whilst 
literature investigating the effects of acetate on autophagy is sparse, accumlation 
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of acetate in the cell by blocking its conversion into acetyl CoA has been shown to 
reduce autophagy in yeast and drosphillia (Eisenberg et al., 2014).  More work is 
required to fully explore the effects of acetate on autophagy, espescially as there 
is no one “gold standard” autophagy test. Therefore, it is recommended to 
combine multiple techniques such as immunobloting for autophagic markers such 
as LC3 and p62,  or the imaging of autophagic structures such as lysosomes 
(Zhang et al., 2016). 
 
3.14.7 | The Effects of Acetate on the Cell Cycle 
 
 The unrestrained proliferation of cancer cells is often a consequence of cell 
cycle dysregulation (Collins et al., 1997), a series of events and checkpoints 
leading up to the division of a cell. These are four major events within a cell cycle: 
G1, duplication of cellular contents, S: the duplication of cellular DNA, G2: checking 
the duplicated DNA for errors, and Mitosis (M); the division of the cell into two. 
Targeting the cycle has been a popular target in cancer chemotherapy (Schwartz 
and Shah, 2005). Not only does inhibition of the cell cycle prevent proliferation, it 
can also induce or sensitize cells to apoptosis (Vermeulen et al., 2003). The 
results from my experiments show that acetate induces a dose-dependent 
increase in G2-M arrest in HCT116 cells. Manipulating the G2-M checkpoint, both 
by bypassing it altogether and arresting cells at that stage, has been shown to 
lead to increased sensitivity to apoptosis (DiPaola 2002). The G2-M checkpoint 
acts as a protective stop-gap, providing a cell time to repair damage to its DNA 
before apoptosis is triggered. This suggests that bypassing the checkpoint could 
increase the effectiveness of DNA-damaging drugs, and indeed agents that inhibit 
G2 checkpoint regulating enzymes have been found to be effective at increasing 
the cytotoxicity of chemotherapeutic drugs (Jackson et al., 2000). In contrast, 
arrest at G2-M has also been identified to improve apoptotic response, for example 
combination treatment with the anticancer drug doxorubicin and silibinin, an active 
ingredient found in milk thistle extract, was found to substantially increase the 
population of cells in the G2-M phase, which resulted in greater induction of 
apoptosis compared to each agent alone (Tyagi et al., 2002). G2-M arrest has also 
been identified in butyrate, and, to a lesser extent, propionate (Matthews et al., 
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2007). However, the authors of this study reflect that the effects of the SCFA on 
the cell cycle may be cell-type dependent, as butyrate treatment has been 
identified to induce G0/G1 arrest in lymphoma cells, although the end result was 
still the induction of apoptosis (Duan et al., 2005).  
Therefore in this study it would have been interesting to compare the effects 
of acetate on each different cell line. However, only HCT116 cells were able to be 
analysed, due to both MCF7 and MCF10A fixing into clumps which blocked the 
flow cytometer. This could be a result of combination of the specific flow cytometer 
having a narrow probe, or difficulty in preparing single cell suspensions following 
ethanol fixation. It is therefore imperative that future work includes repeating this 
assay on MCF7 and MCF10A cells. In addition, further work is needed to identify if 
the observed G2-M arrest is linked to the acetate-induced effects on the 
mitochondria. 
Also interesting to consider is the relationship between the cell cycle and 
ROS. In Section 1.3.5.1 it is discussed that by modulating the redox state of the 
cell, ROS production can effectively regulate the cell cycle. Since ROS is elevated 
in HCT116 following acetate treatment, it may be possible that the observed G2-M 
arrest is caused by ROS production. Such a mechanism has been identified in 
cardamonin, an extract of the cardamom spice. In that study, it was reported that 
the cardamonin-induced G2-M arrested was caused by increased expression of 
cyclin D1 and p21, an effect that was reversed using the ROS inhibitor n-acetyl-L-
cysteine (NAC) (Li et al., 2017). Similar mechanisms have been identified in other 
natural products, such as in human osteosarcoma cells treated with erianin, an 
extract of the Chinese orchid Dendrobium chrystoxum (Wang et al., 2016) and in 
lung adenocarcinoma cells treated with curcubatin B, a triterpenoid found in many 
plants (Guo et al., 2014). As was found in cardamonin, the G2-M arrest effect of 
erianin and curcubatin B was inhibited by treatment with NAC. Therefore, 
additional experiments should include studies of the effect of NAC following 






3.14.8 | The Effects of Acetate on Gene Expression 
 
It is well documented that the SCFAs can alter gene expression (Astakhova 
et al., 2016). To further examine these effects in a metabolic context, I measured 
the expression of genes related to acetate metabolism, namely ACSS1 and 
ACSS2, as well genes involved in the regulation of mitochondrial processes that 
have so far been examined; VDAC1 for the regulation of mitochondrial Ca2+, Nrf2 
for the regulation of the cell’s defences against oxidative stress, and p53, which 
regulates the cell cycle and apoptosis.  
 
3.14.8.1 | The Effect of Acetate on ACSS1 and ACSS2 Expression 
 
The proteins ACSS1, localised to the mitochondria, and ACSS2, localised 
to the cytosol, catalyse the conversion of acetate into acetyl CoA – the primary 
metabolic fate of acetate (Schug et al., 2016). Changes in the expression of both 
genes are well documented in cancer, with the silencing of both being associated 
with decreased cancer cell viability (Yun et al., 2009) and reduced tumour 
formation in mice models (Comerford et al., 2014). The increased expression of 
ACSS2 in particular is linked to an aggressive cancer phenotype, thought to be as 
a consequence of the increased carbon contribution of acetate into biosynthetic 
and energetic pathways in cancer cells (Lakhter et al., 2016). In my study, acetate 
treatment caused an increase in ACSS1 in MCF7, and a decrease in MCF10A – 
although neither change was statistically significant compared to the untreated 
controls. ACSS1 was not expressed in HCT116. ACSS2 expression on the other 
hand was significantly higher in MCF7 and MCF10A. Even though higher 
expression of ACSS2 is linked to tumour survival, increased expression has been 
observed as a response to metabolic stress (Schug et al., 2015), and so this 





3.14.8.2 | The Effect of Acetate on VDAC1 Expression 
 
The VDAC1 gene encodes the VDAC1 channel on the OMM, which 
enables the exchange of metabolites, notably ATP and Ca2+, between the 
mitochondria and cytosol. This key function in metabolism has led to VDAC being 
described as a “governor” of mitochondrial function and metabolism (Lemasters et 
al., 2012). As such, the levels of expression of VDAC are of particular interest to 
scientists with respect to a variety of disease states, such as Parkinson’s and 
cancer (Camara et al., 2017). In cells treated with acetate, there was a trend 
towards increased expression of VDAC1 in each cell line; although only in 
MCF10A cells did this increased expression reach statistical significance 
compared to untreated cells. Increased expression of VDAC1 has been linked to 
increased mitochondrial permeability and apoptosis (Liu et al., 2011), as well as 
enhanced sensitivity to DNA cross-linking agents such as cisplatin  (Sharaf El Dein 
et al., 2012). Increased intracellular Ca2+ has been shown to upregulate VDAC1 
expression (Weisthal et al., 2014) – and as acetate treatment is shown to induce 
increased intracellular Ca2+, this provides a plausible explanation for the observed 
increased expression in VDAC1. VDAC is also known to have anti-apoptotic roles; 
binding by HK has been shown to protect against Bak/Bak-induced apoptosis. This 
role however is determined by HK expression, which was not measured in this 
study. 
 
3.14.8.3 | The Effect of Acetate on Nrf2 Expression  
 
Nrf2 encodes a transcription factor that regulates the expression of a 
number of antioxidant proteins as part of the cell’s response against oxidative 
stress. Under normal conditions, Nrf2 is broadly expressed, but its activity is 
suppressed by Kelch like-ECH-associated protein 1 (KEAP1) and Cullin 3 which 
together rapidly turnover Nrf2 via ubiquination, which marks proteins for 
degradation via the proteasome. Oxidative stress disrupts the structure of Cullin 3, 
disrupting the ubiquitination pathway and allowing Nrf2 to accumulate in the 
cytosol. Nrf2 then translocates to the nucleus, where it associates with a family of 
proteins called the small Maf proteins. These dimers then bind to antioxidant 
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response elements on DNA, upstream of a variety of antioxidant genes, inducing 
their transcription (Qiang, 2013; Yamamoto et al., 2008). In the present study, Nrf2 
expression was significantly decreased in acetate treated HCT116 cells, whilst 
expression in MCF7 and MCF10A were unaffected by acetate treatment. The 
reduced expression may explain the greater ROS response and decrease in 
mitochondrial respiration in HCT116 cells compared to MCF7 and MCF10A 
following acetate treatment, as Nrf2 KO cells demonstrate impaired mitochondrial 
function, diminished mitochondrial membrane potential, and elevated levels of 
ROS (Holmstrom et al., 2013). This effect is particularly interesting with respect to 
priming, since inhibiting Nrf2 expression has been identified as a means to 
sensitise bile duct cancer cells to cisplatin induced cell death (Sompakdee et al., 
2018). 
 
3.14.8.4 | The Effect of Acetate on p53 Expression    
 
 p53 encodes what is perhaps the most well-known tumour suppressor 
protein, tumour protein 53. It’s role in the suppression of cancer progression is well 
documented, as it affects various mechanisms including cell cycle arrest, 
activation of DNA repair, and the initiation of apoptosis should DNA repair fail 
(Ozaki and Nakagawara, 2011). p53 has also been shown to directly regulate 
apoptosis by localising to the mitochondria-ER interface following stress, 
facilitating movement of Ca2+ from the ER into the mitochondria, causing 
mitochondria Ca2+  overload and subsequent apoptosis (Giorgi et al., 2015).   
In HCT116, p53 expression was significantly reduced by treatment with 
acetate. Expression levels were unaffected by acetate in MCF7 and MCF10A 
cells. The loss of p53 in HCT116 in this context is somewhat surprising 
considering the well-defined role of p53 in cancer cells; loss of p53 function is 
observed in more than half of human cancers (Ozaki and Nakagawara, 2011). 
However, the observed decrease in p53 expression may contribute to the state of 
oxidative stress induced by acetate treatment in HCT116 cells, as it is also shown 
to play an antioxidant role. Sablina et al. observed that siRNA inhibition of p53 
caused an elevation of intracellular ROS (Sablina et al., 2009). Additionally, the 
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role of p53 in DNA repair and protection against DNA damage may contribute to 
resistance to DNA targeting drugs (such as cisplatin), and so a reduction in 




3.14.8.5 | Conclusions on the Effect of Acetate on Gene Expression 
 
 Despite consistent responses across cell lines in metabolic markers such 
as viability, ROS and Ca2+, the effect that acetate had on the expression of the 
genes studied appeared to follow no apparent cohesive pattern. This discrepancy 
may be as a result of acetate’s role as a HDAC inhibitor (Brody et al., 2017; 
Soliman and Rosenberger, 2011). Described in Section 1.8.3.4, HDACs are a 
class of enzyme that catalyse the removal of acetyl groups from histones, causing 
DNA to wrap more tightly around them, restricting the access of the transcription 
machinery and thus inhibiting gene expression (Barneda-Zahonero and Parra, 
2012). By inhibiting these enzymes, acetate can affect gene expression by 
modulating the binding of transcription factors and other regulatory proteins to 
DNA. Thus, acetate could be affecting the expression of a large number of genes 
beyond the scope of what was investigated in this thesis, and with no one 
particular gene targeted over another. The non-specificity of HDAC inhibition is 
clear in the development of HDAC inhibitors as drugs, which are shown in clinical 
trials to exhibit broad side effects.  It is therefore crucial to discover the exact roles 
of individual HDACs in different types of cancer (Chen et al., 2015). 
 It is also interesting to note that the despite the varying effects of acetate 
on gene expression, the overall effect of acetate on cellular metabolism was 
consistent across the three cell lines. This may indicate the oxidative stress 
induced by acetate can be accentuated through different epigenetic mechanisms 
across the different cell types. To address these points, future work should 
examine the effects of acetate on a much wider range of genes, by employing 
techniques such as DNA microarray analysis.  
Finally, it is important to recall that changes in gene expression may not 
always correlate to changes in protein expression or even protein activity. 
Therefore, this section of work can be verified by protein quantification, not 





3.14.9 | The Effects of Short Term Acetate Treatment on Mitochondrial Function and 
Intracellular Ca2+ 
 
The focus of my work thus far has explored the effects of acetate 24 hours 
following treatment. In vivo, exogenous SCFA treatment has been shown to be 
metabolised within 60 minutes in mice (Ge et al., 2008), so to provide a clearer 
mechanistic picture as to how acetate induces oxidative stress 24 hours after 
treatment, I studied the effect of acetate in a shorter time period. Using the 
SeaHorse, I found that the injection of acetate caused an immediate increase in 
mitochondrial respiration, which was sustained across the total 12 hours of the 
assay, which is in contrast to the observations that mitochondrial respiration is 
decreased 24 hours following acetate treatment. The increase after 12 hours was 
statistically significant only in HCT116 cells, although similar trends were observed 
MCF7 and MCF10A cells. The increase in OCR was accompanied by an 
immediate drop in ECAR, again sustained over the 12 hours of measurement, and 
this decrease was significantly lower than the control in each cell line. This would 
suggest that acetate is inducing an immediate increase in OXPHOS and 
subsequent decrease in glycolysis. This suspected change in glycolysis was 
investigated in more detail using the SeaHorse GlycoStress test, which confirmed 
a significant decrease in glycolysis in each cell line. As with OCR, the effect was 
most pronounced in in HCT116 cells, in which decreases in glycolytic capacity (a 
measure of the cell’s capacity to respond to the energetic demand of stress) and 
glycolytic reserve (a measure of the cell’s ability to utilize glycolysis beyond the 
basal rate) were observed.  
 The next step was to investigate how acetate is causing this 
immediate change in mitochondrial function. One of the mechanisms that has 
been discussed in this study is the interaction between calcium signalling and 
oxidative phosphorylation.  
As mentioned in Section 1.8.3.3, acetate acts as a ligand for the g-coupled 
protein receptors FFAR2 and FFAR3, displaying the greater affinity for FFAR2 
(Brown et al., 2003). FFAR2 Is coupled to both GQ and Gi/o signalling pathways. 
The binding of a ligand to a g-coupled protein that is coupled to the Gq pathway 
results in the cleavage of phosphatidylinositol 4,5-biphopshate (PIP2) into 
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diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). IP3 interacts with the 
Ca2+ channels on the endoplasmic reticulum, triggering the release of Ca2+ into the 
cytosol, increasing intracellular Ca2+ (Berridge, 1993). I therefore hypothesised that 
acetate treatment would induce an acute increase in intracellular Ca2+. This has 
been reported following treatment with butyrate by Miletta et al., who also 
demonstrated that silencing FFAR2 and FFAR3 inhibited the butyrate-induced 
increase in intracellular Ca2+ (Miletta et al., 2014). The rapid increase in Ca2+ was 
observed in HCT116 and MCF10A cells, and although an increase was seen in 
MCF7, the effect size was small and may warrant further study. It is known that 
Ca2+ can increase the rate of OXPHOS (Hajnóczky et al., 1995; Hawkins et al., 
2007), which has been observed in this project in response to acetate treatment. 
Interestingly, MCF7, which displayed the smallest Ca2+ response to acetate 
treatment, also displayed the smallest change in OCR. These results would 
indicate that acetate treatment causes an increase in mitochondrial respiration via 
FFAR2 and FFAR3 mediated Ca2+ release. Future work to test this hypothesis 
should include the knockdown of FFAR2 and FFAR3 to examine whether this 
blunts the Ca2+ response to acetate treatment.   
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3.15 | A Summary of the Effects of Acetate 
  
The results of this chapter are briefly summarised in Table 12, which shows 
that 24-hour acetate treatment has a similar effect on cancer and non-cancer cell 
lines, save for two important distinctions. 24-hour treatment had no effect on non-
cancerous mitochondrial respiration and no effect on the number of mitochondria 
per cell (although the average mitochondrial mass per cell was decreased). Acute 
acetate treatment also appeared to have no significant effects on the non-
cancerous cell line.  
 Cancerous Cells 
Non-Cancerous 
Cells  
MEASURE ACUTE TREAMENT 
Mitochondrial Respiration Increased1 No significant effect 
Glycolysis Decreased No significant effect 
Intracellular Ca2+ Increased No significant effect 
 24 HOURS POST ACETATE TREATMENT 
Cell Viability No significant effect No significant effect 
Apoptosis No significant effect No significant effect 
Mitochondrial Respiration  Decreased No significant effect 
Reactive Oxygen Species Increased Increased 
Intracellular Ca2+ Increased Increased 
Mitochondrial Number Decreased No significant effect 
Mitochondrial Area No significant effect Decreased 
 






The results would indicate whilst acetate treatment does not induce cell 
death in any of the cell lines studied here, it causes a state of oxidative stress 
(decreased mitochondrial function) in the cancerous cell lines through a specific 
mitochondrial pathway (increased ROS, Ca2+ and decreased mitochondrial 
number). Even though similar pathways were affected in the non-cancerous cell 
line, the effects did not seem to be sufficiently robust to induce a state of oxidative 
stress. The consequences of these differences, and what it means for acetate as a 
priming agent, are discussed in Section 6.   
Table 12 | Summary of the Effects of Acetate. Cancerous cells: HCT116 and MCF7. Non-
cancerous cells: MCF10A. Results were only considered decreased or increased if they were 
significantly different to their respective controls. Results that were not significantly different 
are labelled “no effect”. Gene expression analysis (for which results were cell-type 




 The evidence gathered in this section strongly suggests that acetate 
interacts with the mitochondria of the cell. The observed decreases in respiration, 
changes in ROS, Ca2+, mitochondrial morphology and gene expression can all be 
linked by opening of the mPTP, leading to a decrease in mitochondrial membrane 
potential (Δψm). Sustained loss of Δψm is a key step in the initiation of apoptosis 
and can be associated the observed with decreases in OXPHOS, increases in 
ROS and Ca2+ and changes in morphology (Zorova et al., 2018). Inducing 
decreased Δψm has been identified as the mechanism by which many molecules 
can sensitise cancer cells to drug-induced cell death, including curcumin (Xu et al., 
2015), ursolic acid (Wu et al., 2016), and neferine (Sivalingam et al., 2017). In 
future, the effect of acetate on Δψm should be investigated both 24 hours after and 
immediately following treatment, which would serve to predict the potential of 
acetate as a priming agent. Based on findings from this section and as well as 
existing chemosensitisiation/priming literature, I would expect acetate to induce 
significant Δψm loss. Several methods are available to measure changes in Δψm, 
including the (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine 
iodide stain (known as JC-1), or the tetramethylrhodamine ethyl ester (TMRE) 




4.0 | Priming With Acetate 
  
The effectiveness of chemotherapeutic drugs is often hampered by 
cytotoxic side effects. The rising incidence in cancer (National Cancer Institute, 
2018) means that there is a need to develop methods of improving the efficiency 
of drugs, new and existing, whilst limiting the side effects experienced by patients. 
Priming, introduced in Section 1.7, is being investigated as a novel technique to 
improve drug efficacy, by manipulating the sensitivity of cancer cell mitochondria 
to apoptotic triggers (Chonghaile et al., 2011; Reed, 2011). Priming cells with 
natural products known to have anti-cancerous properties has been successfully 
demonstrated with compounds such as CBD (Henley, 2015) and curcumin (Zou et 
al., 2018).  In this section, I investigate the use of acetate, a SCFA, as priming 
agent. Acetate is well documented to have chemopreventative effects both in vitro 
and in vivo (Brody et al., 2017). This, in combination with its availability from diet 
and circulation make it an attractive target as a priming agent. 
 To test this, I treated HCT116, MCF7 and MCF10A cells with acetate prior 
to, and in combination with, the widely used chemotherapeutic drug, cisplatin 
(DDP), the mode of action of which is well established (Section 1.5.1.2). In Section 
3, I observed that treatment with 10 mM acetate induced a number of effects 
consistent with a state of cellular and mitochondrial stress, including enhanced 
ROS production, increased levels of intracellular Ca2+, decreased mitochondrial 
function and alterations in mitochondrial morphology. A heightened level of stress 
can mean a cell is more likely to initiate apoptosis when faced with a second 





The priming protocol, including times between priming agent treatment and 
DDP treatment (see Section 2.13), and concentrations of DDP, was based of 
published priming work (Henley, 2015), as well as the elevated mitochondria 
stress markers seen at 24 hours following acetate treatment in Section 3. In this 
section of the study I compared 3 treatment protocols (see also Table 10, Section 
2.17): 
1.) Priming: 24 hour acetate treatment followed by 24 hour DDP treatment 
2.) DDP alone: 24 hour control treatment followed by 24 hour DDP treatment 
3.) Combination: 24 hour media treatment followed by 24 hour acetate and 
DDP treatment 
In this chapter, the objective was as follows:  
• To determine that if pre-treatment (priming) with acetate enhances the 




4.1 | Effects of Priming with Acetate on Cellular Viability  
 
The effects that priming, cominbation treatments, and DDP alone treatment 
had on HCT116, MCF7, and MCF10A cell viability compared to the untreated 
control were analysed by the MTT Viability assay (Figure 36). 
In HCT116, all treatments caused a signifcant decrease in cellular viabilty 
compared to the untreated control. Priming with 10 mM acetate caused a 
significant decrease in cellular viabilty compared to treatment with 100 µM DDP 
(50.03 ± 2.65% vs 75.64 ± 3.60%, p = 0.001). 1 and 5 mM acetate priming 
treatments had so signifcant effect on viabilty  compared to DDP treatment. 
Addiotnally Combination treatment had no significant effect on viabilty to 
compared to DDP treatment.   
In MCF7, there was again a significant decrease in cell viabilty compared to 
the untreated control for all treatment groups. 1, 5 and 10 mM acetate-primed 
treatments all showed a significant, dose-dependant decrease in cell viablity 
compared to DDP treatment (1 mM acetate primed: 68.39 ± 3.88% p = 0.032, 5 
mM acetate primed: 67.36 ±  2.34% p = 0.021 and 10 mM acetate primed: 60.74 ± 
2.28% p = 0.001 vs DDP: 85.17 ± 2.83%). The combination treatment had no 
signifcant effect on vialbilty compared to DDP treatment alone. 
In the control cell line MCF10A, all treatments showed a signifcant 
decrease in cell viabilty compared to the untreated control. 1, 5 and 10 mM 
acetate priming treatments had no signifcant effect on cellular viability compared 
to DDP treatment alone. 
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Figure 36 | The Effect of Priming with Acetate on Cell Viability. Bars represent mean cellular 
viability as percentage of the negative control (100%, indicated as horizontal dashed line) ±SEM 
of at least n = 5 independent experiments. Differences between treatment groups and untreated 
control analysed via Unpaired Students T-Test. # indicates significant (p <0.05) decrease in 
viability compared to negative control. Differences in the mean cell viabilities between treatment 
groups assessed via 1-way ANOVA followed by Tukey’s Multiple Comparison Test * indicates 























































































































































































































4.2 | Effects of Priming with Acetate on Apoptosis 
 
To investigate whether priming with acetate sensitises cells to DDP-induced 
cell death, the Annexin-V PI assay was used to measure apoptosis (Figure 37). In 
HCT116, priming with 10 mM acetate caused significant increases in apoptosis 
compared to DDP treatment alone (24.13 ± 4.53% vs 10.96 ± 0.769%, p = 0.038).  
In MCF7, priming with 10 mM acetate also caused a significant increase in 
apoptosis induction compared to DDP treatment (44.94 ± 3.22% vs 34.84 ± 
1.38%, p = 0.028) 
 In the control cell line MCF10A, priming with acetate had no significant 






Figure 37 | The Effect of Priming with Acetate on Apoptosis. Bivariate dot plots 
(Representative) show cells/events plotted as function of Annexin V and PI MFI. Events in 
bottom right and top right quadrants were considered apoptotic.  Bars represent mean 
percentage of total apoptotic events ±SEM from n = 5 individual experiments. Differences 
between priming and DDP-treated analysed with Unpaired Student’s T-test. * indicates 




























































































4.3 The Effect of Priming on Mitochondrial Function 
 
 Next, I analysed the effect of priming with acetate on mitochondrial function 
using the MitoStress Assay on the SeaHorse XFe24 Flux Analyser. Only HCT116 
cells were analysed (Figures 38 and 39) due to DDP treatment cells to detach 
from the surface of the SeaHorse plates. This is discussed in more detail in 
Section 4.4.2. 
 Priming with acetate and treatment with DDP both caused a large decrease 
in the basal respiration, which was significant compared to the untreated control in 
DDP treated cells (16.47 ± 8.22% of the control p = 0.009) and trending towards 
significance in primed cells (33.09 ± 18.31% of the control p = 0.067). The 
difference between primed and DDP-treated cells was not significantly different. 
 For the maximal rate of respiration, DDP treatment caused a large 
decrease in OCR compared to the untreated control (32.15 ± 15.44% of the 
control p = 0.0481). Priming appeared to have no significant effect on maximal 
respiration. The difference between primed and DDP-treated cells was not 
significantly different p = 0.531). 
 For ATP-associated OCR, rates were significantly decreased in DDP 
treated cells (17.27 ± 7.89% of the control p = 0.009), but not primed cells). The 







Figure 38 |The Effect of Priming with Acetate on Mitochondrial Respiration. Bar graphs show 
the individual parameters of the MitoStress test of HCT116 cells, presented as the mean 
percentage of the negative control ±SEM of n = 3 independent experiments. · indicates 
significance (p <0.05) with regards to the negative control. * indicates significance between 



















































































































Figure 39 | The Effect of Priming with Acetate on Mitochondrial Respiration - OCR Profiles. 
(Representative) show change in HCT116 OCR over course of the MitoStress Assay. A: Data OCR 
normalized to protein content, measured via Bradford Assay. B: Unadjusted OCR data  
A 
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4.4 | Discussion 
 
4.4.1 | The Effects of Acetate Priming on Cell Viability and Apoptosis 
 
Results from Chapter 3 present demonstrated that acetate treatments alone 
can modulate the function of cancer cell mitochondria, whilst having no effect on 
cell viabilty or the induction of cell death. The next stage in the project was 
therefore to investigate if these effects translate into increased sensitivity to 
apoptosis: does acetate prime cells for death?  
As with the investgation into the effects of acetate on viabilty and apotosis 
induction, the MTT assay was used to screen for a priming effect, followed by 
confirmation using the Annexin V flow cytometry assay. The results indicate that 
cancer cells undergo signficantly enhanced levels of apoptosis when primed with 
aceate compared to DDP treatment alone. Furthermore, this effect was not 
observed in the non-cancerous MCF10A cell line. Addtionally, the sensitization 
effect is not observed when acetate and DDP are added to cells simultaneously 
(combination treatments). These findings provide clear evidence that acetate, 24 
hours after treatment, is capable of sensitising cancer cells for death. From this, 
combined with data gathered on the health of acetate-treated mitochondria, it can 
be concluded that the observed sensitization to apoptosis is caused by priming the 
mitochondria of cancer cells to death.  
This is the first time a SCFA has been demonstrated to enhance the 
sensitivity of cancer cells to drug-induced cell death. Future work should 
investigate whether propionate and butyrate exhibit a similar effect to acetate – 
indeed, one might predict a stronger effect given that propionate and butyrate 
have been shown to initiate apoptosis alone (See Section 1.8 and 3.3), although 
this may complicate their potential as priming agents, as they may affect non-
cancerous cell viability. Acetate joins a growing list of naturally occur molecules 
that have potential as priming agents (See Section 1.7, Table 5). It is interesting to 
consider the mechanisms by which these other priming agents induce 
chemosensitisation. Quercetin, a flavonoid found in many plants and foods, was 
found to induce apoptosis via inhibition of the pro-survival Akt pathway, as well as 
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through the down regulation of superoxide dismustase, which leading to 
accumulation of ROS, resulting in increased sensitivity of cancer cells to DDP 
treatment (Sharma et al. 2005). El-Senduny et al. found cucurbitacin B, another 
compound found in plants, to induce sensitivity to DDP treatment in ovarian cancer 
cells through G2/M arrest and again, increased ROS production (El-Senduny et 
al., 2015). Finally, cannabinol (CBD) was shown by Henley to induce 
chemosensitvity of breast cancer cells to DDP treatment through modulation of 
mitochondrial function, including changes in ROS and Ca2+ (Henley, 2015). The 
mechanisms of each of these natural products draw parallels to the effects of 
acetate treatment observed in this study, namely; the induction of oxidative stress 
through elevated ROS levels. Acetate however stands out in such comparisons to 
other priming agents as in this thesis, I have shown that it can sensitise different 
types of cancer cell line to death, an observation which highlights the potential of 
acetate to improve the treatment of different cancers. 
 A significant limitation in this section was the effect of DDP on MCF10A 
cells; in the MTT viability assay, the amount of cell death induced by DDP reduced 
the viability of cells below the detectable limit of the plate reader, and so the 
concentration of DDP used for this cell line in this part of the study had to be 
reduced to 50 µM. This was not a limitation on the Annexin V-FITC assay, which 
used larger seeding densities and is also more sensitive. To prevent this issue, 
dose response assays should have been carried out to determine a median lethal 
dose (LD50) to determine the appropriate concentration of DDP to use for 




4.4.2 | The effects of Priming on Mitochondrial Function 
 
 By observing mitochondrial function following priming treatments, I set out 
to investigate whether there was any difference in mitochondrial function between 
cells that had been primed with acetate and those that were treated with DDP 
alone. When normalized to protein content, both primed and DDP-treated cells 
exhibited a significant decrease in mitochondrial function compared to untreated 
cells, consistent with what would be expected in a population of cells undergoing 
or having undergone apoptosis (Lomeli et al., 2017). There was no significant 
difference in the mitochondrial function between primed and DDP-treated cells, 
despite treatment with acetate alone being shown in this study to significantly alter 
mitochondrial function (See Section 3.5). I would attribute this to the significant cell 
death induced by DDP; which I speculate would mask any effect priming had 
different from DDP treatment alone. The level of cell death also posed 
experimental problems, apparent in the large variation in response to treatment 
observed in this Section. Accurate OCR data is dependent on an evenly 
distributed monolayer of cells (Aglient, 2017), and although the Bradford Assay 
was used to correct for changes in cell population, it was difficult to ensure an 
even monolayer, as cells undergoing apoptosis are likely to detach. These issues 
made it difficult to obtain meaningful data for MCF7 and MCF10A, which often 
detached and failed to provide data within the detection limits of the SeaHorse 
analyser.   
 Based on these findings and the experienced difficulties, it was decided not 
to look further at the metabolism of cells following priming, as any observations 
would be dominated by DDP-induced apoptosis in both experimental conditions. 
This is further apparent in Figure 40, which shows the stark contrast in 
mitochondrial morphology between untreated and DDP-treated cells.  
Furthermore, as the aim of this study was to determine if and how acetate primes 







Figure 40 | The Effect of DDP on Mitochondrial Morphology. Cells in images labelled 
untreated received media for 24 hours. Cells in images labelled 100 µM DDP were treated with 
100 µM DDP for 24 hours. For clarity, a green LUT was applied and brightness was adjusted 
with ImageJ’s “Auto” settings.  
Untreated 
100 µM DDP 
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5.0 | 2P FLIM of NADH as a 
Measure of Cellular Metabolism 
 
5.1 | 2-Photon Microscopy  
 
The pools of cellular NADH and NADPH regulate the balance between 
driving energy production and maintaining antioxidant defences. In particular, 
NADH/NAD+ links the TCA cycle to the production of ATP in oxidative 
phosphorylation (Blacker and Duchen, 2016). Thus, levels of NADH/NAD+ can 
provide information regarding the metabolic state of the cell (See Section 1.3.8 for 
more detail). NADH is fluorescent, whilst its oxidised counterpart, NAD+ is not and 
therefore the intensity of NADH fluorescence can provide meaningful information 
as to the metabolic state of a cell without the need for an external probe (Sanchez 
et al., 2018). However, the absorption maxima for NADH is 340 nm, in the UV 
region of the electromagnetic spectrum, and so exposure of cells to light of this 
wavelength is phototoxic. UV can damage cells in a number of ways; the most 
well-known being the damage to cellular DNA: UV light initiates a fusion reaction 
between thymine molecules. If this damage is too extensive for the DNA repair 
systems to fix, p53 will direct the cell to apoptosis (Hoeijmakers, 2009). 
Additionally, absorption of UV light by chromophores in skin cells can generate 
ROS (de Jager et al., 2017), which as discussed in Section 1.3.5 are harmful at 
high concentrations. To circumvent this problem, 2-Photon Microscopy can image 
cells with lower energy light of a higher wavelength (Vergen et al., 2012). In a 2 
photon (2P) system, molecules in the ground state are excited by simultaneous 
stimulation by 2 photons, providing sufficient energy to move a molecule to its 
excited state with longer wavelengths (Figure 41).     
There are a number of additional advantages that 2P microscopy provides 
compared to single photon systems (also Figure 41). The probability that a 
molecule will absorb 2 photons simultaneously increases with excitation intensity; 
meaning 2P fluorescence is much higher where the laser is focused. This is 
means 2P microscopy has small excitation volume, reducing out-of-focus noise 
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(Svoboda and Yasuda, 2006). Additionally, the longer wavelengths used in 2P 
microscopy, approaching the infrared, make it ideal for imaging thicker specimens, 
as light in this region is scattered less than visible light used in conventional 
microscopy (Blacker and Duchen, 2016). Despite these advantages, 2P 
microscopy has a lower spatial resolution compared to single-photon, as resolution 
of a microscope is inversely proportional to the wavelength of light used. Thus, a 
2P system, using an excitation wavelength twice of that used in a single photon 




Figure 41 | The Principles and Advantages of 2-Photon Excitation. A: Jablonski diagrams 
comparing one photon and two photon excitation in terms of energy levels. On the left, one 
photon of a long wavelength excites a molecule from the ground to the excited state. In a two 
photon system, as shown on the right, 2 photons, each approximately double the wavelength 
the single photon system provides sufficient energy to promote the same molecule to its 
excited state. B: The probability of 2P absorption increases with beam intensity, meaning the 
“excitation volume” (indicated by circles) is smaller in 2P microscopy, resulting in a less out of 
focus signal. Additionally, longer 2P excitation wavelengths are subject to less scattering than 
wavelengths in the visible spectrum used in single photon systems, meaning the focal place 





5.2 | Basics of Fluorescence Lifetime Imaging Microscopy  
 
Figure 41 shows that fluorescence occurs when a molecule returns to the 
ground state from an excited state. This process is not 100% efficient, as a 
molecule in its excited state can also dissipate its energy through a number of 
non-radiative de-excitation mechanisms, including the transfer of energy to 
neighbouring molecules, known as quenching (Blacker et al., 2014). A high degree 
of non-radiative de-excitation increases the rate at which a molecule returns to the 
ground state from its excited state (Olympus, 2019). The length of time for this to 
occur is called the fluorescence life time decay. NADH has been observed to 
exhibit two distinct fluorescence lifetime decays; ~0.4 ns for free NADH, and ~2.0 
ns for enzyme-bound NADH (Blacker and Duchen, 2016) (Figure 42). A shorter life 
time for free NADH is unsurprising given that the NADH molecule is free to move 
in solution and dissipate its energy to neighbouring molecules. The longer life time 
for bound NADH was considered to be a consequence of enzymes “shielding” 
NADH in binding sites and blocking it from potential quenching events, although 
now is now thought to also be as a result of enzyme binding physically reducing 
the conformational freedom of NADH, preventing another non-radiative de-
excitation mechanism called internal conversion (Blacker et al., 2013).  
Measuring the lifetime decay in a cell can therefore inform us as to the ratio 
of freely diffusing and enzyme-bound NADH, and thus provide more detailed 
information as to the metabolic state of the cell than measuring NADH 
fluorescence alone. To do this, 2 photon microscopy is combined with fluoresce 
lifetime imaging (FLIM), which essentially performs a series of single fluorescence 
lifetime measurements across a field of view to generate an image in which each 





Although FLIM was conceived and developed in the early 1990’s (Takatoku 
et al., 1993), the development of more powerful microscopes and photon counting 
techniques has meant 2P-FLIM has experienced a recent resurgence in popularity 
(Suhling et al., 2015). Most notable among these is time-correlated single-photon 
counting (TCSPC), which allows the detection of single photons with their arrival 
times from a sample with respect to a reference source to picosecond accuracies. 
By exciting the sample millions of times per second, TCSPC generates a 
probability distribution histogram of photon arrival times, which is the fluorescence 
Figure 42 | Fluorescence and Lifetimes of NAD(P)H.  NADH fluoresces (indicated by the blue 
aura) and has a short decay of ~0.4 ns when freely diffusing in solution. When bound to an 
enzyme, this decay increases to around ~2.0 ns. NAD+ is not fluorescent.  
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Figure 43 | The Lifetime Decay Curve of NAD(P)H. Image is a lifetime decay curve obtained 
from one pixel of an image of MCF7 cells using SPC image analysis software. Y axis: number of 
detected protons. X axis: time in nanoseconds. Vertical black line at the left hand side indicates 
the excitation pulse. To calculate lifetimes, SPCimage analysis software calculates multi-
exponential best fit (red line) of detected photons (blue dots). The goodness of fit, measured 
by Pearson’s chi-squared test, is shown in the top left. τ1 and τ2, on the right of the curve, are 
the calculated life time decays of free NADH and bound NADH respectively. α1 and α2 are the 
contributions of each lifetime to the overall decay. 
decay curve of the sample. Such a curve is shown in Figure 43. Because of its 
signal-to-noise ratio, wide dynamic range and single photon sensitivity, TCSPC is 
considered the gold standard of FLIM techniques (Suhling et al., 2015).  
In principle, as the spectral properties of NADH and NADPH are identical, 
there is an issue with resolving between the two species. This separation of NADH 
and NADPH remains a challenge in the field (Blacker et al., 2014). However, 
NADPH lifetime decay has been found to be insensitive to metabolic changes 
(Ghukasyan and Kao, 2009; Vishwasrao et al., 2005), which allows changes in 
lifetime decay to be primarily attributed to NADH, with minimal contribution from 
NADPH. 
In this chapter, I use 2P-FLIM to observe the impact of acetate treatment on 
NAD(P)H metabolism in collaboration with Professor Stan Botchway at the 
Rutherford Appleton laboratory. The objectives in this chapter are twofold: 
1. Measure the effect of acetate on NADH metabolism. 
2. Improve and create a robust protocol for using FLIM to analyse drug 
interactions with cells.  
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In these experiments only MCF7 cells were used due to availability of cells at the 







5.3 | The Effects of Acetate on NADH Lifetime Decay 
  
The effect of acetate on NADH lifetime decay, as a measure of cellular and 
mitochondrial metabolism, was measured using 2P FLIM (Figures 44, 45 and 46).  
 
 
Figure 44 shows a representative FLIM image of MCF7 cells treated with 
either DMSO (the negative control) or 10 mM acetate for 24 hours. As described in 
Section 5.2, each pixel of the image has its own calculated lifetime decay curve 
(similar to the example shown Figure 43). Using the SPC Image analysis software, 
a FLIM image can display a colour-coded heat map for any measured parameter, 
which in the case of this experiment are: the lifetime of free NADH (τ1, or τFree), the 
lifetime of bound NADH (τ2, or τBound), the contribution of free NADH to the decay 
curve (α1, or αFree), and the contribution of bound NADH to the decay curve (α2, or 
αBound) (see Table 12).  
The images in Figure 44 are αBound encoded, where red pixels have a lower 
αBound value, and blue pixels have a higher αBound value. From these acquired 
images, two observations can be made: acetate did not appear to have a large 
effect on αBound and that the signal intensity is much higher in the mitochondria.  
To draw more quantitative conclusions as to changes in NADH lifetime 
between treatments, I compared lifetime decay parameters between DMSO and 
acetate treated cells from pixels within the mitochondrial with pixels within the 
cytosol (Figure 45). In the mitochondria, treatment with 10 mM acetate caused a 
significant increase in the mean lifetime of free NAD(P)H, τFree compared to the 
untreated control (505.9 ± 12.26 picoseconds (ps) vs 475.1 ± 9.22 ps  p = 0.045). 
The mean lifetime of bound NAD(P)H, τBound in untreated cells was unaffected 
DESIGNATION PARAMETER MEANING 
Τ1 TFree Lifetime of free NADH (in picoseconds) 
Τ2 TBound Lifetime of bound NADH (in picoseconds) 
α1 αFree Contribution of free NADH to the overall 
decay curve (percentage) 
α2 αBound Contribution of bound NADH to the overall 
decay curve (percentage) 
Table 12 | Terms Used to Describe NADH Lifetime in 2P-FLIM. The symbols and parameters 
used in this study to describe the lifetime decay curve of NADH 
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compared to acetate-treated cells (2912 ± 57.98 ps vs 2881 ± 46.74 ps (p = 
0.6817). The contribution of τBound (also known as αBound) to the overall lifetime 
decay was  unaffected by acetate treatment.  
In cytosolic pixels, treatment with acetate had no effect on τFree compared to 
the untreated control. τBound was again unaffected by acetate treatment, while 
αBound was significantly higher in acetate-treated cells (29.55 ± 0.868% vs 26.71 ± 
0.605% p = 0.006). 
In comparisons between mitochondrial and cytoplasmic values within the 
same treatments (Figure 46), τBound was significantly higher in the mitochondria 
than the cytosol of control-treated cells. (2912 ± 57.98 ps vs 2708 ± 69.46 ps p = 
0.027). When treated with acetate, there was no significant difference between 
mitochondrial and cytosolic τBound values.  
There was no significant difference in contribution of bound NADH (αBound) 
to the overall lifetime decay between mitochondria and the cytosol of control-
treated cells. Treatment with 10 mM acetate caused a significant decrease in 
mitochondrial αBound compared to the cytosolic αBound (26.19 ± 0.64%, vs 29.55 ± 





















Figure 44 | The Effect of Acetate on NAD(P)H Lifetime Decay: 2P FLIM Images. 
Representative αBound encoded 2P FLIM images of MCF7 cells treated for 24 hours with DMSO 
(left) or 10 mM acetate (right). Images were encoded so that red pixels have a low αBound and 


























Figure 45 | The Effect of Acetate on NAD(P)H Lifetime Decay. Top: Lifetime of free NADH (τ1) 
in the mitochondria and cytosol. Middle: Lifetimes of bound NADH (τ2) in the mitochondria 
and cytosol. Bottom: contribution of Bound NADH (α2) in the mitochondria and the cytosol. 
Data points indicate values from individual pixels ±SEM of n = 3 individual experiments. 
Significance compared to the untreated control indicated by * = p < 0.05, ** p <0.01. No 









































































































Figure 46 | The Effect of Acetate on NAD(P)H Lifetime Decay: Mitochondria and Cytosol 
Comparisons. Bars indicate average value ±SEM from n = 3 individual experiments. Differences 
between control and acetate treated values analysed with Unpaired Student’s T-test. 
Significance compared to the untreated control indicated by * = p < 0.05, ** p <0.01. No 











































5.4 | Discussion 
 
5.4.1 | The Effects of Acetate on the Lifetime Decay of NAD(P)H 
    
In this section, I set out to measure changes in metabolism caused by 
acetate by investigating changes in the fluorescence life time decay of NADH.  
 
Data presented in Section 5.3 indicates that acetate treatment increases 
the decay lifetimes of free NADH (τFree) and the contribution of bound NAD(P)H to 
the lifetime decay curve (αBound) (Figure 45). The length of lifetime is related to the 
environment surrounding NADH. The significant increase in both mitochondrial 
and cytosolic τFree in acetate treated cells could therefore indicate an increase in 
the concentration of freely diffusing NADH [NADHfree]. However, the use of τFree is 
not widely reported in the literature, and could potentially be considered an artefact 
of the fitting process, since these shorter lifetimes are close to the resolution limit 
of the detection system (Blacker et al., 2014).  
 
Of more interest to investigators is the lifetime of bound NADH (τBound) and 
the contribution of τ2 (αBound), variations in which can indicate changes in the 
concentration of enzyme-bound NADH, which in turn can indicate the cell’s 
metabolic state. In acetate treated cells, τBound in both mitochondrial and cytosolic 
pixels remained unchanged compared to the control. A decrease in τBound has been 
associated with increased levels of glycolysis, as oxidative phosphorylation is a 
major site for NADH binding (Skala et al., 2009). Based on SeaHorse data from 
Section 3.5, in which acetate was observed to cause a decrease in OXPHOS after 
24 hours, one may have predicted a decrease in τBound in acetate-treated cells. 
Furthermore, αBound was found to be significantly increased in the cytosol, 
suggesting that treatment with acetate increases the ratio of cytosolic bound:free 
NADH. In the mitochondria, αBound was unchanged compared to the control, which 
again would seem to contradict earlier results indicating mitochondrial stress. 
However, there was a significant difference in αBound between mitochondrial and 
cytosolic pixels in acetate treated cells, which suggest that acetate does have an 
effect on NADH metabolism. One possible explanation for this is that in the face of 
decreased OXPHOS as a result of acetate-inducted oxidative stress, glycolysis 
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rates increase to ensure cell survival. In glycolysis, NAD+/NADH is bound by 
glycerldehyde 3-phosphate dehydrogenase, the enzyme that catalyses the 
conversion of glyceraldehyde 3-phosphate and 1,3-biphosphoglycerate (Sirover 
1999). However, the lack of change in αBound in the mitochondria still contradicts 
what would be expected based on earlier work on acetate and metabolism. 
Further work will be needed to explore these observations.  
 
An interesting finding came from observation of the acquired FLIM images 
(Figure 44): that the signal intensity was noticeably higher in mitochondrial pixels. 
Whilst from a biochemical point of view this may be unsurprising (as NAD+ is 
converted to NADH in the TCA cycle within the mitochondrial matrix), it may 
present the opportunity to make morphological measurements of mitochondria in 
addition to acquisition of FLIM data. Without the need of a fluorescent probe, this 
has an advantage as a non-invasive measure of morphology, and circumvents 
caveats with traditional mitochondrial probes, such as membrane potential 
dependency (discussed in Section 3.14.5). However, similar resolution limitations 
still apply as they did with single photon confocal microscopy, and as in these 
experiments I used a format of 512x512 (to increase the acquisition time and to 
reduce laser exposure to cells), it was not possible to test whether NADH FLIM 
images could be used instead of conventional probes. Therefore, future work 
could include higher resolution FLIM acquisition to compare to conventional single 
photon confocal microscopy.  
 
There are several weaknesses in this analysis which should be noted. First, 
DMSO was used as a negative control, whereas media had been used in other 
sections of this project. Whilst the working concentration used was very low 
(<0.01% volume/volume), future work should repeat the experiments using media 
as the control. Secondly, the data points gathered were from individual pixels from 
each obtained image. Whilst steps were taken to minimise subjectiveness, there 
was no way to ensure true randomness in selection. In addition, pixel to pixel 
variation could affect the data gathered. In future work, steps should be taken to 
reduce any unintentional bias, and to use a region-of-interest approach to analyse 
whole mitochondria, rather than single points. Unfortunately, this was not possible 
in this study as the resolution of the obtained images made it difficult to distinguish 
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mitochondrial boundaries. Finally, there are studies that suggest the rates of 
OXPHOS and glycolysis do not correlate with NAD(P)H lifetime decay as directly 
as initially proposed, and that the relationship is “considerably more nuanced” 
(Blacker et al., 2014; Guo et al., 2015). The use of known mitochondria-affecting 
drugs, such as oligomycin and FCCP, may improve the understanding of this 
relationship and provide greater insight to the results I have gathered thus far. 
Furthermore, the use of 2P-FLIM to investigate such metabolic effects, and the 
identification of issues and nuances of the technique is valuable for advancing 
such studies, which at present are sparse due to the limited availability of the 
instruments. Some current improvements which should be considered in future 
work include the use of a 4-component decay fit (1 component for free NAD(P)H 
and 3 for bound) to improve the resolution of data (Vishwasrao et al., 2005), or the 
phasor approach, described by Digman et al., which plots the raw FLIM data in a 
vector space, which they propose simplifies analysis by avoiding the 
computational difficulties of exponential fitting and providing a graphical, global 





6.0 | Final Conclusions  
  
6.1 | A Proposed Mechanism for Acetate Priming 
 
Priming the mitochondria of cancer cells for death presents a novel 
opportunity to increase the efficiency of new and existing anti-cancer drugs. 
Acetate, a SCFA produced in the gut as a by-product of fermentation, has been 
shown to possess anti-tumorigenic properties and so has potential as a priming 
agent. In this thesis I have further characterised the effect that treatment with 
acetate has on cancer cell lines, finding that acetate, whilst not inducing cell death 
alone, induces a state of oxidative stress, characterised by decreased 
mitochondrial function, increased levels of ROS and intracellular Ca2+, changes in 
cell cycle state, changes in gene expression, and the morphology of mitochondria. 
I have also shown that after priming with acetate, cancer cells exhibited increased 
levels of apoptosis following treatment with cisplatin, compared to treatment with 
the drug alone. Importantly, this effect was not observed in the non-cancerous 
cells.  
 A suggested mechanism based on evidence gathered in this project for how 
acetate primes cancer cells for death is shown in Figure 47. I propose that through 
interactions with the g-coupled protein receptors FFAR2 and FFAR3 on the cell 
surface, acetate induces the release of Ca2+ from the endoplasmic reticulum. In 
turn, the increase in intracellular Ca2+ increases the rate of mitochondrial 
respiration. This drives the production of ROS, as a by-product of OXPHOS. 
Finally, the accumulation of ROS causes a state of oxidative stress - priming the 
cells for the death. There may also be secondary contributing mechanisms, such 
as the changes in gene expression, mediated by acetate’s reported activity as a 
HDAC inhibitor, and the effects on the cell cycle – also linked to elevated ROS. 
The key to this hypothesis are the interactions with FFAR2 and FFAR3, and as 
such, future work should include knockdowns of the genes that express these 
receptors. Miletta et al. had shown that butyrate-induced increase in intracellular 
Ca2+ was muted by FFAR2 and FFAR3 knockdowns (Miletta et al., 2014), but as 
there is a lack of work studying acetate interactions, it would be important to 
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investigate whether the priming effect of acetate changes when the expression of 
the two receptors is altered. Overall, the proposed mechanism can be thought as 
“burning out” the mitochondria: by “pushing” mitochondrial function, acetate 
















































































































































































































































































































































































































6.2 | Future Work 
 
This thesis utilised a cell line model, which are invaluable for initial studies 
due to the relative ease of handling, infinite replication and homogeneity, all of 
which allow direct comparisons between experiments  (Burdall et al., 2003). 
However, it is widely accepted that there are numerous disadvantages compared 
to the use of primary cell lines or animal models. These include genetic and 
phenotypic drift over the extended passage of cell lines (Kaur and Dufour, 2012), 
potential contamination (Olarerin-George and Hogenesch, 2015), cross-
contamination, and the lack of some of the key characteristics of cancer, such as 
the development of the  tumour environment and  metastasis  (Katt et al., 2016). 
Furthermore, the lack of cellular and molecular heterogeneity compared to a 
tumour means cell lines provide only a much-simplified model of cancer (Choi et 
al., 2014). It is therefore imperative that future work must include the use of more 
biologically relevant models, such as 3D cultures and in vivo models. 
The proposed mechanism described in Section 6.1 effectively hinges on 2 
key points: 1.) that the sensitivity of cells treated with acetate is a result of ROS-
induced oxidative stress driven by Ca2+ interactions with the mitochondrial 
respiratory machinery, and 2.) the increase in Ca2+ is a result of acetate 
interactions with the free fatty acid receptors on the cell surface. To further test this 
mechanism, future work should include dissipating the ROS effect by use of a 
ROS scavenger or antioxidants (e.g. NAC), which interestingly has been shown to 
be effective in alleviating oxidative stress in a mouse model of sepsis (Hou et al., 
2010). Furthermore, knockdowns of FFAR2 and FFAR3, which have been shown 
to inhibit butyrate induced Ca2+ release (Miletta et al., 2014), could be investigated 





6.3 | Final Comments 
 
The results gathered from this study point to a complex and multifaceted 
role of acetate in cancer cells, dependent on its source, cell type and treatment 
time. Nevertheless, I have shown that priming with acetate has the potential to 
improve the effectiveness of chemotherapy.  
This thesis reveals for the first time a complex interaction between the 
SCFA acetate and the mitochondria and demonstrates that manipulating the 
function of mitochondria can result in cancer cell-specific sensitivity to death. The 
proposed mechanism of acetate – an initial increase in mitochondrial respiration 
followed by subsequent oxidative stress, is a novel approach to inducing 
chemosensitivity and may warrant investigation in other natural products. Through 
investigating the effect of acetate on NADH metabolism, I also demonstrate that 
2P FLIM has potential to provide a non-invasive method to measure mitochondrial 
metabolism and morphology simultaneously. Finally, this thesis adds more 
evidence to the case for priming, demonstrating that this approach may be 
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